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ABSTRACT OF THE DISSERTATION 
DEVELOPMENT OF POINT-OF-CARE TESTING SENSORS FOR BIOMARKER 
DETECTION 
by 
Xuena Zhu 
Florida International University, 2015 
Miami, Florida 
Professor Chenzhong Li, Major Professor 
Point-of-care testing (POCT) is defined as medical testing at or near the site of patient 
care and has become a critical component of the diagnostic industry. POCT has many 
advantages over tests in centralized laboratories including small reagent volumes, small size, 
rapid turnaround time, cost-effectiveness, low power consumption and functional integration 
of multiple devices. Paper-based POCT sensors are a new alternative technology for 
fabricating simple, low-cost, portable and disposable analytical devices for clinical diagnosis. 
The focus of this dissertation was to develop simple, rapid and low cost paper-based 
POCT sensors with high sensitivity and portability for disease biomarker detection. Lateral 
flow strips (LFS) were used as the basic platform as it provides several key advantages such 
as simplicity, fast response time, on site and cost-effectiveness, and it can be used to detect 
specific substances including small molecules, large proteins and even whole pathogens, in a 
sample by immunological reactions. Earlier designs of paper strips lacked the quantitative 
information of the analyte concentration and could only provide single analyte detection at a 
time. In this study, a series of modifications were made to upgrade the platform to 
compensate for these limitations. 
vii 
 
First, we developed a gold nanoparticle based LFS for qualitative colorimetrical 
detection of bladder cancer related biomarkers in standard solutions and in urine samples. 
Second, by incorporating an image processing program “ImageJ”, a semi-quantitative LFS 
platform was established. The capability of the strip was evaluated by testing a small DNA 
oxidative damage biomarker in urine and cell culture models. Third, we combined the 
electrochemical method and colorimetrical method for quantitative biomarker detection. 
Finally, we integrated a commercialized blood glucose meter to quantitatively detection of 
two non-glucose biomarkers by converting their signals to that of glucose. The upgraded 
sensor could provide a noninvasive, rapid, visual, quantitative and convenient detection 
platform for various disease biomarkers. In addition, this platform does not require expensive 
equipments or trained personnel, deeming it suitable for use as a simple, economical and 
portable field kit for on-site biomarker monitoring in a variety of clinical settings. 
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Chapter 1. Introduction 
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1.1. Motivation 
The motivation of this dissertation was to develop paper-based point-of-care testing (POCT) 
sensors with high sensitivity, specificity, speed of performance and the advantages of 
simplicity for disease biomarker detection. POCT is defined as medical testing at or near the 
site of patient care. The driving notion behind POCT is to bring the test conveniently and 
immediately to the patient. This fundamental research could potentially benefit early disease 
diagnosis, which allows for immediate clinical management decisions to be made. Lateral 
flow immunochromatographic assay (LFIA) or simply lateral flow strip (LFS) were used as 
the basic platform as it provides advantages such as simple, rapid and low cost, and it can be 
used to detect various substances in a sample by using an immunological reaction. However, 
earlier designs of paper strips lacked the quantitative information of the analyte concentration 
and could only provide single analyte detection at a single time. To overcome these 
limitations, we applied the software “ImageJ” to semi-quantify the tests, integrated a paper 
electrode to carry out quantitative electrochemical measurements, and finally upgraded the 
platform to make it suitable to be combined with the commercialized blood glucose meter for 
universal biomolecule detection. The goal of this dissertation was to develop a noninvasive, 
rapid and quantitative detection method for disease biomarkers. In addition, the developed 
POCT sensor does not require expensive equipment or trained personnel, deeming it suitable 
for use as a simple, economical, portable field kit for on-site biomarker monitoring in a 
variety of clinical settings. 
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1.2. Specific aims 
Specific Aim 1: To develop gold nanoparticles (AuNPs) based LFS and evaluate its ability to 
detect three bladder cancer (BCa) related biomarkers and an oxidative DNA damage 
biomarker. 
 
LFS is the simplest and earliest design of paper-based POCT platform, and it has been widely 
used as in-field and POCT diagnostic tools for monitoring biological molecules and chemical 
contaminants. LFS were used as the basic platform throughout the entire dissertation study, 
thus, the first aim of the dissertation research was to fabricate a AuNPs based LFS. The 
reliability of the strip was first evaluated by three BCa related biomarkers (Creatinine, Matrix 
metallopeptidase 9 (MMP-9) and vascular endothelial growth factor (VEGF)) for their 
qualitative colorimetrical analysis. Then, by incorporating an image processing program 
“ImageJ”, the strip was upgraded for semi-quantitative detection of a small DNA oxidative 
damage biomarker (8-hydroxy-2’-deoxy-guanosine, 8-OHdG). To the best of our knowledge, 
this is the first LFS-based sensing platform with the capability of 8-OHdG detection. This 
sensing platform could also help study nanomaterials induced toxicity within cells. 
 
We expected to rapidly detect three BCa related biomarkers as well as 8-OHdG with high 
sensitivity by our developed LFS platform. The toxicity of three metallic nanoparticles in 
vitro was also investigated and estimated by measuring the concentrations of 8-OHdG after 
particles exposure, whose feasibility was validated by the comparison with two other 
established methods, Alamar Blue assay and Electrical impedance sensing (EIS) system. 
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Specific Aim 2: To integrate an electrochemical sensing component to the LFS platform to 
develop a device which combining the electrochemical and colorimetrical sensing 
methodologies for biomarker detection 
 
A colorimetrical assay can only provide a qualitative or semi-quantitative analysis of the 
analytes, which is not a specific enough result in many cases. Electrochemical detection is an 
attractive method due to its capability of quantitative analysis, easy miniaturization to 
provide a portable formation, and less incident background. Many studies have focused on 
applying electrochemical detection to the traditional paper-based POCT analytical devices in 
order to compensate for the limitations of colorimetric detection. The major concern with the 
measurement of 8-OHdG by the electrochemical method is the potential interference of 8-
OHdG containing short nucleotides. As the products of 8-OHdG repairing, both the 8-OHdG 
molecule and 8-OHdG containing short nucleotides are present in biological urine samples, 
with 8-OHdG forming the major component usually. Existence of 8-OHdG containing short 
nucleotides will significantly quench the signaling in electrochemical assay set up with 
parameters for the 8-OHdG molecule. The occurrence and proportion of 8-OHdG containing 
short nucleotides are relatively similar in normal biological samples, but might vary 
appreciably across normal person and patients. To overcome the drawbacks of the 
immunostrip assay and electrochemical method for 8-OHdG detection, the second aim deals 
with the development of an novel electrochemical immunosensor (ECIS) which integrates 
carbon nanotubes (CNTs) paper electrodes with a immunochromatographic strip for 
quantitative analysis of 8-OHdG in both PBS buffer and urine samples. 
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We expected that the new sensing device could combine the competitive AuNPs based lateral 
flow immunoassay with miniaturized paper electrodes for both colorimetrical and 
electrochemical detection. This novel platform could provide a fast diagnostic tool for 
quantitative DNA oxidative stress assessment with high sensitivity and specificity. 
Furthermore, the integrated platform can be further upgraded and optimized into a wireless-
enabled biosensing system in future for telemedicine applications. 
 
Specific Aim 3: To integrate personal glucose meters with the traditional lateral flow 
immunostrip for portable and quantitative detection of biomarkers 
 
We successfully coupled the electrochemical sensing platform to the LFS in the previous 
specific aim. An important superiority of the coupled platform is that it can be potentially 
connected to a portable electronic device for quantitative and instant measurements, which is 
a key perspective for the future POCT development. At the same time, electrochemical 
detection usually based on a fact that the analyte itself should be electrochemically 
detectable. Therefore, in the specific aim 3, we tried to test an electrochemical integrated LFS 
platform by directly connecting to a portable device, which can detect any analytes with or 
without electrochemical properties by electrochemical method. The personal glucose meter 
(PGM) is one of the most successfully commercialized diagnostic devices on the market and 
it has been widely used by millions of diabetic patients to monitor their blood glucose levels 
every day because of its low cost, compact size, simple operation and reliable quantitative 
results. In order to take advantages of this well established technique, a novel design that 
combines the traditional LFS with a commercial PGM was developed for quantitative 
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detection of non-glucose targets. A small molecule, 8-OHdG, as well as a large protein, 
prostate specific antigen (PSA), were used as model analytes for concept demonstration. 
 
We expected that the new device could quantitatively detect non-glucose targets by using a 
PGM. The results obtained from PGM-based method were compared with those from 
commercialized ELISA kits, demonstrating the feasibility of the new platform. Considering 
the inherent advantages of the PGM, the demonstration of this device therefore should 
provide new opportunities for the monitoring of a wide range of biomarkers as well as 
various target analytes in connection to different molecular recognition events. 
 
1.3. Point of care testing 
1.3.1. Definition and significance of POCT 
POCT, also known as near patient or bedside testing, is any analytical test performed outside 
the laboratory, normally at or near the site of patient care.1 Many of the early “diagnostic 
tests” were first done at the bedside—for example, urine testing. Over the past few years, 
however, analytical systems have been developed that enable a wide range of tests to be done 
quickly and simply without the need for sophisticated laboratory equipment.2 
  
The driving notion behind POCT is to bring the test conveniently to the patient and to obtain 
immediate results of the testing so that appropriate treatment can be implemented, leading to 
an improved clinical or economic outcome. The use of POCT has been around for over 50 
years, however there has be a recent increased use in the hospital and community settings due 
to rapid advances in genomics, transcriptomics, and proteomics which has accelerated the 
unraveling of disease pathogenesis, the discovery of disease biomarkers, and the 
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identification of pathogens. In addition, the emerging fields of nanotechnology and 
microfluidics have improved assay designs and performance, thereby bringing accurate and 
sensitive diagnostic tests to POCT.3  
 
The main advantage of POCT is a rapid turnaround time, generating results sooner and 
therefore allowing for more immediate patient triage and effective treatment or discharge. 
This can lead to improved patient care, earlier discharge from the hospital, reduced medical 
costs and contribute towards reducing government waiting time targets. In addition to saving 
time, some POCT tests have been modified to simplify the test procedure, reduce the chance 
of operator error, and directly use a body fluid sample without pretreatment.3 Successful 
design will eliminate the need for prior knowledge in sample analysis and can be performed 
by an outpatient or by any ward personnel. 
 
1.3.2. Biosensors in POCT 
POCT devices often employ biosensors (Figure. 1.1). A biosensor is commonly defined as an 
analytical device that combines a biological component with a physicochemical-detector 
component for the detection of analytes. This generally occurs through the use of 
miniaturized analysis systems, where biological components are immobilized on a solid-state 
surface, which, in turn, interacts with the analyte.4 These interactions may be detected by 
using either electrochemical or optical methods.  
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Figure 1.1. Schematic of biosensor 
 
POCT analyzers currently available can be separated into various groups. Type 1: Qualitative 
strip-based POCT methods. Type 2: Unit-use analyzers, the simplest form of quantitative 
POCT device. For these two types of devices, most of the analysis takes place on the test 
strips and the reader is used only to read the results from the strips where the reaction has 
already taken place. Examples of type 2 include glucometers for home and the hospital 
POCT stations and the i-STAT Abbott (Abbott Park, IL, USA), a multi-parameter unit-use 
POCT instrument.5 Type 3: Bench-top POCT analyzers, are generally more complex than 
unit-use machines and use different analytical principles, such as spectrophotometric 
substrate and enzyme-activity measurement; hematological particle counting; immunoassay; 
and, sensor-based blood-gas analysis.6 Type 4: Hemostaseological coagulation analyzers, 
these POCT compatible machines show a high degree of complexity; although they are valid 
for use in POCT, only qualified personnel should operate them. Type 5: Continuous 
measurement with POCT systems, the most common example being continuous glucose 
monitoring,7 and these systems are already available commercially. Type 6: Molecular 
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biology-based POCT devices used to detect infectious agents. The currently available novel 
POCT systems are in part forerunners of a new generation of laboratory systems which will 
dominate the market in 10–20 years’ time (fourth-generation laboratory systems). These 
methods are characterized through miniaturization, parallel analyses and networking via 
information technology (IT).6  
 
1.3.3. Telemedicine developed with POCT 
Emerging Internet technologies are used to create and manage a Virtual Laboratory 
Information System (VLIS), integrated into a distributed healthcare environment. The main 
objective of the system is to organize the transference of clinical testing from the traditional 
large central laboratories to a cooperative scheme of several manageable POCTs.8 Emerging 
information technologies allow these POCTs to be essentially connected within Hospital 
Information System (HIS) distributed environments, sharing on-line healthcare data among 
the different actors involved in patient treatment, which is also referred as telemedicine.  
 
The fundamental parts of the telemedicine system are: the measuring devices (e.g., sensors), 
a device (e.g., mobile phone, IPAD) to format the readings for a communications link, a 
clinic server to which the data is transmitted, a database for storing the data, and a display of 
the data obtained from the server. Mobile devices are one of the most common methods 
employed and have been widely used for data collection and processing. The trend of using 
mobile and wireless communication for bio-sensing applications is becoming more and more 
apparent. For data collection, nano-structured materials will be used to build fully-integrated, 
non-invasive and bio-inspired wireless/mobile sensor for health monitoring including heart 
rate, blood glucose concentration, as well as different bimolecular levels. After data 
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collection, wireless/mobile devices will be continuingly used for the transmission of medical 
information to the hospital or health centre. For the patient, there is no longer the need to 
make an appointment with the doctor or to spend time and cost traveling only to receive a 
benign result. The systems can also be used to monitor the health condition of patients and to 
aid them in making a clinical decision as early as possible, an advantage for both disease 
control and therapy. From a clinical standpoint remote monitoring allows patients to record 
their readings in a more relaxed home environment, rather than to undergo the stress of 
travelling for a personal consultation. 
 
1.4. Paper-based sensors 
1.4.1 Unique properties of paper as a platform for disposable diagnostic devices 
Paper is a well-known material for writing, printing, drawing and packaging. The potential 
utility of paper beyond these simple and traditional means stems from its unique properties, 
which include the following: it is available and manufactured in every part of the world very 
cheaply; it is biodegradable as well as biocompatible; it is flexible, easily coated and 
imprinted; it is made of a porous cellulose structure, so it wicks fluids and eliminates the 
requirement of an active pumping mechanism; its porous structure also serves as a filter for 
many analytical applications; and it is usually white and serves the best platform for 
colorimetric and fluorescent detection.9  
 
1.4.2. Significance and development of paper-based sensors 
Paper has been used in analytical laboratories since the early 20th century with a significant 
revolution when Martin and Synge were awarded the Nobel Prize for the invention of paper 
chromatography in 1952.10 Over the years, with the development of novel nanomaterials and 
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nanofabrication technologies, many interesting and innovative concepts and prototypes for 
paper-based bioanalytical devices have been reported. 
 
In 1956, the first paper device for the semi-quantitative detection of glucose in urine was 
demonstrated,11 that further developed into immunochromatographic paper test strips (also 
known as lateral flow or dipstick tests), with the pregnancy test kit being a well-known 
example.12 Although reliable, these simple and low cost devices are generally limited in 
providing a qualitative “yes/no” type of detection. The last few years has seen a shift in focus 
from basic design concepts to more advanced fabrication and patterning techniques in order 
to obtain more accurate and quantitative results. Whitesides and co-workers13, 14 introduced 
the idea of fabricating microfluidic channels on paper for multiplex analyte detection. Since 
then, many new areas of fabrication and exploration have opened up, such as in paper-cut 
microfluidic devices15-18 and microfluidic separation devices.19-21 These new research 
avenues have resulted in sensors that can be analyzed by techniques other than colorimetry,13, 
14, 22-25 such as by electrochemical,26-28 chemiluminescence29 and electrochemiluminescence30 
methods.  
 
Due to their enormous advantages, paper-based analytical devices can play vital roles in 
improving diagnostics and treatment of various diseases in resource-limited areas of the 
world, which are financially incapable of having advanced technologies.13 A low-cost paper-
based analytical device can fulfill the need of people in developing and poor regions of the 
world, which lack the facility of proper infrastructure and trained healthcare professionals at 
the site of patients.13  
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1.5. Lateral flow immunochromatographic assay (LFIA) or LFS 
LFIA, also called lateral flow tests or simply strip tests, is the simplest and earliest design 
used for an analytical device platform. This technology offers additional advantages when 
compared to the conventional detection methods given that it is rapid, simple and cost-
effective in comparison. The first application of strip assay was the pregnancy test with the 
detection of human chorionic gonadotropin (HCG) in the early 1980s.31 The speed of the 
results observed directly by the naked-eye and the utilization of a membrane strip as the 
immunosorbent material provided an analytical platform that permits a one-step, rapid and 
low-cost analysis. To date, this technology has reached many fields of research such as 
pathogens and infectious diagnostic, food and environment monitoring. Figure 1.2 shows the 
typical design of LFS, having four major components: sample pad, conjugation pad, reaction 
membrane and absorbent pad. Typically, when a sample is applied, the antigen will bind to 
an antibody on the conjugation pad (conjugation antibodies are conjugated to signal 
molecules such as latex beads, colloid gold, etc.). The complex formed due to the 
antigen/conjugate antibody interaction then travels along the paper membrane through 
capillary action and is subsequently captured by antibodies available on the reaction zone of 
the paper strip.10 A color change can be visualized with the naked eye within a few minutes, 
which indicates of the presence of the target analyte in the sample. However, earlier designs 
of paper strips were criticized for only providing a qualitative, ‘yes/no’ signal and lacked 
the quantitative information of the analyte concentration.32 Moreover, such designs can only 
provide single analyte detection at a single time and they are difficult to integrate with 
multiple analyte detection.32 
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Figure 1.2. Lateral flow strip 
 
To overcome the limitations of earlier LFS designs, such as single analyte detection, lack of 
quantitative information and lack of control over sample flow, many novel manufacturing 
techniques have been developed. In this dissertation study, we chose to use LFS as the basic 
platform as it provides several key advantages such as simplicity, fast response time, on site 
and cost-effectiveness, and it can be used to detect various substances in a sample by using 
an immunological reaction. Nevertheless, we reduced the disadvantage by integrating several 
novel techniques to the original platform. First, we applied a image processing program-
ImageJ to the original colorimetrical measurements to semi-quantify the results. Second, we 
combined the traditional platform with a flexible paper electrode, which could perform a 
quantitative electrochemical detection beside the colorimetrical result. Third, to 
enlarge the application scope of test strip, we integrated the commercialized blood glucose 
meter with an upgraded platform, which can provide new opportunities for the monitoring of 
a wide range of biomarkers as well as various target analytes in connection to different 
molecular recognition events. Based on these improvements, the new strips can provide a 
noninvasive, rapid, visual and quantitative detection method for disease biomarkers. In 
addition, this method does not require expensive equipment or trained personnel, deeming it 
 
14 
 
suitable for use as a simple, economical, portable field kit for on-site biomarker monitoring in 
a variety of applications. 
 
1.5. Biomarker detection 
1.5.1 Biomarkers 
A biomarker generally refers to a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention. Detection of biomolecules has been of significant 
interest in areas such as genomics, proteomics, medical diagnostics and environmental 
monitoring.  
 
Lateral flow strips have been widely used to semi-quantitatively or quantitatively measure the 
concentration of common analytes, that is, glucose, HCG and BSA in a variety of body fluids 
(i.e. urine, blood, sweat, etc.) for a long period of time. Nowadays, by incorporating the new 
techniques, the paper-based devices can be further applied to many other biomarkers. 
 
Cancer becomes one of the leading causes of death with more and more people being 
diagnosed with cancer every year. Currently, treatment efficiency of late stage cancer is poor. 
However, cancer at early stage is generally treatable, and the early detection of cancer is in 
urgent need. Cancer diagnosis is very important and becoming a practical way to improve the 
cure rate. Cancer biomarkers exist in body fluids or tumor tissues and encompass a wide 
range of molecules, including transcription factors, cell surface receptors and secreted 
proteins. It can be used for detection and can also help doctors to make decisions on patients 
as early as possible about the possible response to a given drug and what the most effective 
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dose might be providing valuable prognostic information. Traditional diagnostic techniques 
are usually costly, time-consuming, require specialized laboratory-based equipment, 
dedicated sample preparation processes and professional operators. Paper-based devices 
simplify the system. Wang et al. combined microfluidic paper-based analytical devices 
(μPADs) with the CL-ELISA for the simultaneous determination of α-fetoprotein, CA125 
and carcinoembryonic antigen in human serum samples.33 Liu et al. developed a disposable 
electrochemical immunosensor diagnosis device that integrates the immunochromatographic 
strip technique with an electrochemical immunoassay, and the device has been successfully 
applied for the detection of PSA in human serum samples.34  
 
Along with cancer diagnosis, paper-based devices can also be used for the detection of other 
diseases. Many studies on diabetes developed methods to quantified glucose, lactate or 
cholesterol in human serum and urine samples by incorporating the electrochemical detection 
with paper-based microfluidic devices.26, 35 In-field and point-of-care diagnosis of genetic 
diseases by DNA–DNA hybrids and dual labels were also developed with one example 
being an ultrasensitive nucleic acid biosensor based on horseradish peroxidase-gold 
nanoparticles dual labels and LFS biosensor.36 A nanoparticle-based electrochemical 
immunosensor has been reported for the detection of phosphorylated acetylcholinesterase, 
which is a potential exposure biomarker for organophosphate pesticides and chemical 
warfare nerve agent exposures.37 Heart-type fatty acid-binding protein is an early cardiac 
marker of acute myocardial infarction, which is the predominant cause of mortality and 
disability in most developed countries38 and requires a rapid assay system. Renneberg’s 
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group developed a quantitative lateral-flow assay for rapid detection of fatty acid-binding 
protein.30  
 
Furthermore, paper-based devices have been widely used in environmental and food safety 
monitoring. Determination of metal ions in waste solutions is important in public health and 
environmental monitoring, for example, measurement of Au(III), Fe(III), Pb(II) and Zn(II) in 
industrial waste solutions by incorporating electrochemical method and microfluidic platform. 
28, 39 Detecting and quantifying mycotoxins is essential for food safety monitoring. One group 
has developed a semi-quantitative detection of Ochratoxin A, a type of mycotoxin, by an 
aptamer-based chromatographic strip assay.40  
 
1.5.2. Detection mechanism by LFS 
The two predominant approaches to the LFS are the non-competitive (or sandwich) and 
competitive (or competitive inhibition) reaction schemes. These can best be explained 
graphically, as shown in Figures 1.3.a and 1.3.b. The double antibody sandwich format is 
used when testing for large analytes with multiple antigenic sites, such as LH, hCG, and HIV. 
In this case, less than an excess of sample analyte is desired so that some of the microspheres 
will not be captured at the capture line, and will continue to flow toward the second line of 
immobilized antibodies, the control line. This control line uses species-specific anti-
immunoglobulin antibodies, specific for the conjugate antibodies on the microspheres. The 
competitive reaction scheme is used most often when testing for small molecules with single 
antigenic determinants, which cannot bind to two antibodies simultaneously. If this format is 
chosen, it is important to pay close attention to the amount of antibody bound to the 
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microspheres in relation to the amount of free antigen. Some of the microspheres will bind at 
the capture line giving a weak signal and making the test result ambiguous. 
 
Three BCa related biomarkers (Creatinine, Matrix metallopeptidase 9 (MMP-9) and vascular 
endothelial growth factor (VEGF)), a DNA oxidative damage biomarker (8-hydroxy-2-
deoxyguanosine (8-OHdG) and a PCa related biomarker (prostate-specific antigen (PSA)) 
were used in this dissertation study as representatives for demonstrating the feasibility and 
applicability of developed platforms (both sandwich and competitive formats of detection).  
 
 
Figure 1.3. (a) Direct (double antibody sandwich) reaction scheme; (b) Competitive reaction 
scheme. Image taken from the website of Bangs Laboratories, inc.. 
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Chapter 2. General experimental methods 
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2.1. Introduction 
In this dissertation study, LFS were used as the basic platform and upgraded further with 
other elements to improve the design and enlarge the application of the strip. Some common 
experimental procedures present in each chapter will be summarized here. 
 
2.2. Fabrication of AuNPs based LFS 
2.2.1. Preparation of AuNPs 
A well-established citrate reduction method41 was employed to generate AuNPs of various 
diameters. Different sizes of AuNPs produce different reflected color. Preliminary data 
shows that AuNPs with a diameter of ~20 nm intrinsically gives a better visibility on paper 
based strip when accumulated on test line, and many studies42-44 also used this size for similar 
applications, therefore we used AuNPs with average size around 20 nm as the labels. 
 
Briefly, hydrogen tetrachloroaurate solution (HAuCl4) (50 mL, 0.01% ) was added to a 
Erlenmeyer flask (250 mL), stirred and brought to the boil on a hotplate. Trisodium citrate 
solution (1 mL, 1%) was added rapidly to the boiling solution under constant stirring. 
Gradually, the color changed from pale yellow to wine red (Figure 2.1). After the color 
change ceased, the solution was boiled for another 10 min and stirred without heating for 
another 10 min to complete the reduction of the gold chloride. The size of the particles were 
characterized by the Zetasizer after the solution reached room temperature. 
 
The wine red colored solution contains AuNPs with a size of approximately 20 nm 
(Zetasizer, Figure. 2.2a) and its corresponding maximum absorbance is exhibited at 520 nm 
as shown in Figure. 2.2b (UV-VIS spectrophotometer). It is well known that the strong 
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absorbance at 520 nm is attributed to the surface plasmon resonance of AuNPs and the 
maximum absorption peak will be shifted or disappeared if the nanoparticles aggregate 
together.45, 46 
 
 
Figure 2.1. Color changes during the preparation of colloidal AuNPs: (a) 0 min, (b) 5 
min, (c) 10 min and (d) 20 min (with an average size ~20 nm). 
 
 
Figure 2.2. (a) Intensity distribution vs. size of AuNPs solution (average size ~20 nm) 
measure by Zetasizer; (b) UV-Vis spectrum of ~20 nm AuNPs 
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2.2.2. Synthesis of antibody conjugated AuNPs 
For antibody labeling, the AuNPs solutions was concentrated 5-fold (5X) in advance and the 
pH was adjusted to 8.0~8.5 with 0.1 M Potassium carbonate (K2CO3). Before conjugation, 
the optimal concentration of the antibody was determinated by following the protocol from Y 
Zhao. et al..47 Simply, antibody solutions with different concentrations were mixed with gold 
solution (5X, pH 8.0~8.5) and incubated for 15 min at room temperature, and then 10% 
Sodium chloride (NaCl) solution was added. The color of samples changes from brilliant red 
to blue as the concentration of antibody decreases (Figure 2.3). The optimum concentration 
for labeling was the lowest concentration of antibody that did not change color. For example, 
five folds (5X) concentrated AuNPs with an optimal concentration 0.5 mg mL-1 of anti-8-
OHdG antibody was used for the DNA oxidative damage study.  
 
 
Figure 2.3. Determination of the optimal mAb concentration for conjugation 
 
Purified antibody (60 µL) with optimal concentration (for bladder cancer biomarkers 
detection: anti-Creatinine pAb, 20 μg mL-1; anti-MMP-9 mAb, 180 μg mL-1; and anti-VEGF 
mAb, 180 μg mL-1. For DNA oxidative damage biomarker detection: mouse anti-8-OHdG 
monoclonal antibody, 0.54 mg mL-1) was added to a tube, which containing 750 µL pre-
concentrated (5X) AuNPs solutions. The mixture was stirred gently at room temperature for 1 
h first, and then stabilized by adding 10% BSA (90 µL) in sodium borate (20 mM) for a final 
concentration of 1% and incubated for another 20 min. After the tube was centrifuged for 15 
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min at 7,000 rcf, two phases were obtained: a clear to pink supernatant of unbound antibodies 
and a dark red, loosely packed sediment of the AuNPs-Abs conjugates. The supernatant was 
discarded and the pellet was resuspended in BSA/PBS (900 µL, 1%). Following the same 
centrifugation step, the supernatant was removed again and the soft sediment of conjugates 
was resuspended in 900 µL buffer 1, which contained sodium phosphate (20 mM), Tween 20 
(0.25%), sucrose (10%), and BSA (5%). Tween 20 provides buffer control and also has a 
slight surfactant quality that aids in resolubilization of the particles. BSA can provide a 
blocking function which can prevent non-specific binding. The sucrose serves as a 
preservative and a resolubilization agent. The final conjugate solution was stored at 4 °C until 
use.  
 
Initially, we used a green fluorescent protein (GFP) labeled antibody as a model to 
demonstrate the feasibility of this conjugation protocol. As illustrated in Figure 2.4a, the 
fluorescence image demonstrated the efficiency of conjugation. Figure 2.4b showed that the 
corresponding maximum absorbance of AuNPs was shifted from 520 nm to 530 nm after 
antibody conjugation. 
  
Figure 2.4. (a) Fluorescence images of the antibody conjugated AuNPs; (b) UV-Vis spectrum 
of ~20 nm AuNPs before and after antibody conjugation 
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2.2.3. Preparation of conjugation pad 
30 μL AuNPs-Ab conjugates solution prepared as outlined in section 2.2.2 was dispensed by 
pipette onto a glass fiber pad (conjugate pad) (5 mm × 9 mm). Following which, all pads 
were dried at room temperature and stored in desiccators at 4 °C before use. 
 
2.2.4. Preparation of reagents preloaded on the nitrocellulose membrane 
2.2.4.1. Preparation of BSA-8 hydroxyguanosine conjugates 
8-hydroxyguanosine (5 mg) was dissolved in NaIO4 (1mL, 50 mM) and the mixture was 
incubated for 1 h in the dark. The reaction was stopped by adding Ethylene glycol (2.5 µL) 
for 5 min. The mixture was then mixed with BSA (2 mL, 25 g L-1, pH=9.5, adjusted by 
K2CO3 (50 g L-1)) under constant stirring dropwise and incubated for another 1 h. After that, 
Sodium borohydride (NaBH4, 2 mL, 24 g L-1) was added and the mixture was incubated in 
the dark at 4 °C overnight (12-16 h). Finally, the conjugates were dialyzed against 1X PBS 
and stored at -20 °C. 
 
2.2.4.2. Preparation of other antibodies 
Creatinine pAb (20 μg mL-1), anti-MMP-9 pAb (36 μg mL-1), anti-VEGF pAb (18 μg mL-1), 
Rabbit anti-Mouse IgG (1 mg mL-1), Rabiit anti-Sheep IgG (1 mg mL-1) and Goat anti-mouse 
IgG (1 mg mL-1) were diluted from the original concentrations which directly obtained from 
manufacture. 
 
2.2.4.3. Buffer used for capture reagent preparation 
Nitrocellulose membranes can bind proteins electrostatically independent of pH, but pH can 
affect the immobilization efficiency of a particular protein by altering its properties in 
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solution. The tendency of the antibody to partition onto the membrane increases as the 
solubility of the capture reagent which is influenced by pH is reduced. Solubility is minimal 
when the protein has no net charge, for example, at the isoelectric point, pI. Thus, to 
minimize protein solubility and maintain a stable solution, the pH was adjusted to the pI of 
the capture reagent. Most antibodies have isoelectric points between pH 6.5 and 9.0. Using a 
buffer at pH 7.0 - 7.5 was commonly recommended by many studies and manufacture. In this 
study, 1X PBS (pH 7.4) was used for capture reagent preparation. 
 
2.2.5. Assembly of the LFS 
A typical test strip consists of four components: sample loading pad, conjugation pad, 
nitrocellulose membrane, and absorption pad, all of which were affixed onto a plastic 
backing plate (Figure 2.5). 
 
The sample pad (5 mm by 19 mm) made of glass fiber was treated with buffer 2 (pH 8.0) 
which contains 0.15 mM NaCl, 0.05 M Tris-HCl and 0.25% Triton X-100 in advance. Use of 
an appropriate buffer minimizes the non-specific adsorption, increases the sensitivity and 
reproducibility of the biosensor. Based on many studies,42-44 we compared the performances 
of different running buffers, and established that buffer 2 yielded the best results. Sample 
pads were then dried at room temperature and stored in desiccators at 4 °C before use. 
 
For BCa related biomarkers detection: Anti-Creatinine pAb (20 μg mL-1), anti-MMP-9 pAb 
(36 μg mL-1) and anti-VEGF pAb (18 μg mL-1) were used as the test line (T) capture 
reagents, while Rabbit anti-Mouse IgG and Rabiit anti-Sheep IgG (1 mg mL-1) were used as 
the control line (C) capture reagent, respectively. 
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For DNA oxidative damage biomarker detection: BSA-8 hydroxyguanosine conjugates were 
used as the test line capture reagent, while goat anti-mouse IgG (1 mg mL-1) was used as the 
control line capture reagent. 
 
For PSA detection: Anti-PSA mAb were used as the test line capture reagent, while goat anti-
mouse IgG (1 mg mL-1) was used as the control line capture reagent. 
 
These capture reagents were dispensed by the Linomat 5 dispenser onto a nitrocellulose 
membrane as test and control lines. Finally, all of components including sample pad, 
conjugate pad, nitrocellulose membrane and absorbent pad were assembled on a plastic 
adhesive backing layer. Each part overlapped 2 mm to ensure the solution migration through 
the strip during the assay (Figure 2.5). 
 
 
Figure 2.5. Typical AuNPs based LFS. 
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2.3. Preparation of standard solutions and samples 
2.3.1. For BCa related biomarkers detection 
Standard solution of Creatinine (Sigma-Aldrich), MMP-9 and VEGF (R&D systems, Inc,) 
(0.03 mg mL-1, 50 ng mL-1 and 120 ng mL-1, respectively) were commercially obtained 
without further processing, and kept at 4 °C before use. After institutional review board 
(IRB) approval, urine samples from 10 potential BCa patients were collected by Dr. Rosser’s 
Translational Research Laboratory (MD Anderson Cancer Center Orlando) and shipped to us 
following the standard procedures. Urine samples were stored at -20 °C after received. 
Before use, urine samples were thawed to room temperature, and then centrifuged at 7,000 
rcf for 10 min. Following which, supernatants were collected, filtered through a Whatman no. 
1 filter paper and stored in a tube. 
 
2.3.2. For DNA oxidative damage biomarker detection and nanotoxicity assessments 
Stock solutions of 8-OHdG (500 μg mL-1) were prepared before use by dissolving the 8-
OHdG powder in purified PBS (1X) solution, DMEM and cell lysis buffer respectively. 
Working standards ((0.1–100000) ng mL-1, (1–80) ng mL-1 and (1–80) ng mL-1) were 
prepared further in the corresponding media. 
 
2.3.3. For 8-OHdG detection by electrochemical method 
8-OHdG standard solutions ((1-1000) ng mL-1) were prepared as outlined in section 2.3.2. 
Urine samples were obtained from drug free, non-smoker, healthy volunteers within the 
department following the protocol approved by both Florida International University (FIU) 
and the Telemedicine and Advanced Technology Research Center [TATRC] IRB. Samples 
were stored frozen (-20℃) in aliquots of 4 mL until analyzed. Before use, urine samples were 
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thawed to room temperature and then centrifuged at 7,000 rcf for 10 min to remove any 
precipitate. Following which, the supernatants were collected and diluted 10-fold with PBS 
(1X) to minimized the interference induced by variation of urine components and further 
used as control. The diluted urine samples were serially spiked with 8-OHdG to make 
solutions of 0, 1, 10, 20, 50, 80, 100, 150, 200 and 1000 ng mL-1 concentration levels prior to 
the test. 
 
2.3.4. For biomarker detection by PGM 
8-OHdG standard solutions ((0.1-200) ng mL-1) were prepared as outlined in section 2.3.2. 
PSA solution were directly obtained from manufacture (Sigma-Aldrich), working standards 
((1-200) ng mL-1) were prepared with 1X PBS before use. Urine samples were prepared as 
outlined in section 2.3.3 without dilution. 
 
2.4. Paper strip assay and colorimetrical analysis 
Standard solution or sample (100 µL) was added onto the sample pad, and the solution 
migrated toward the absorbent pad. Photographs were taken by a digital camera or scanner 
after 10 min for further colorimetrical analysis. 
 
2.5. Detection mechanism for LFS 
There are various possible formats of LFS depending on the type of target analyte.48 The two 
kinds of format frequently used are sandwich assay and competitive assay. 
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2.5.1. Sandwich assay 
Sandwich assay format (Fig. 2.6A) was employed to test analytes presenting several epitopes 
such as cancer protein biomarkers (i.e. MMP-9, VEGF and PSA). The sandwich assay can 
employ two different antibodies (polyclonal and monoclonal) that bind distinct epitopes of 
the analyte: a labeled monoclonal or polyclonal antibody is placed in a dehydrated state onto 
a glass-fiber membrane (conjugate pad) to serve as detector reagent and a polyclonal or 
monoclonal antibody specific to the analyte is sprayed at the test line of the nitrocellulose 
membrane to serve as the capture reagent. An additional antibody specific to the detection 
antibody could be used to produce a control signal. When a sample extract is applied to 
sample pad, the liquid migrates up by capillary force and the detector reagent is then 
released. Some of the analyte binds to the detection antibody and some will remain free in the 
solution. Subsequently, the mixture passes through the capture zone and both unbound 
analytes and bound analytes bind to the capture antibody. The response in the capture zone 
(test line) is directly proportional to the amount of analyte in the sample.49  
 
2.5.2. Competitive assay 
The competitive format is employed most often when testing analytes with low molecular 
weight or presenting a single antigenic determinant.50 In a competitive format (Fig. 2.6B), an 
analyte-protein conjugate (e.g. 8-OHdG-BSA) coated on the test zone of a nitrocellulose 
membrane captures a labeled anti-analyte monoclonal antibody complex, allowing color 
particle (e.g. colloidal gold) to concentrate and form a visible line on the test zone. Another 
specific antibody coated on the control line allows the capture of the excess antibody 
complex. One band of color will therefore be visible in the control zone regardless of the 
presence of target analytes or not, confirming correct test development. Conversely to 
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sandwich, a negative sample will result to the formation of two band colors visible (test line 
and control line),51 and the intensity of the test line is inversely proportional to the amount of 
analyte in the sample. 
 
 
Figure 2.6 Schematic representation of lateral flow tests with sandwich format (A) and 
competitive format (B). In sandwich format the response on the test line is proportional to the 
analyte concentration. In contrast, with competitive format the signal response on the test line 
is inversely proportional to the analyte concentration. (+) = positive; (–) = negative. The 
lower line is the test line and the upper line is the control line. 
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Chapter 3. Development of gold nanoparticles based LFS and its applications on the 
detection of bladder cancer related biomarkers and an oxidative DNA damage biomarker 
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3.1. Development of LFS for bladder cancer related biomarker detection 
3.1.1. Introduction 
In the last decade, progresses in technologies have driven a new era in the analysis of both 
biological agents and chemical contaminants. These analytical techniques have been 
described and reviewed extensively in the literature.52-55 Most of them are sensitive and 
specific, but suffer from being time consuming, laborious and multi-complex. In addition, 
these technologies are unaffordable to the farmers and some laboratories in the developing 
countries. Therefore, there is an emergent need to develop highly accurate, rapid and cheap 
analytical tools. To achieve this goal, many attempts have been focused on the development 
of rapid POCT such as LFS. LFS is a well-established diagnostic tool in laboratory and has 
been continually developed in the last three decades.  It has been widely used as in-field and 
POCT diagnostic tools for monitoring biological warfare agents, infectious diseases and 
cancer.35, 37, 40, 42-44, 56-63  
 
Cancer of the urinary bladder is a common malignancy worldwide.64, 65 Bladder cancer (BCa) 
can be classified into two groups based on histopathology and clinical behavior: non-muscle 
invasive papillary tumors (Ta or T1) (80%) and muscle invasion tumors (20%). Nevertheless, 
more than 70% of patients with Ta/T1 lesions confined to the mucosa will have recurrence 
during the first two years. If left untreated these initially non-invasive lesions can progress to 
being muscle invasive.66, 67 The recurrence phenomenon of non-invasive bladder tumors 
makes BCa one of prevalent cancers world-wide and is therefore a great burden to healthcare 
systems.68 Gold standard for initial clinical diagnosis and staging of BCa involves 
cystoscopic examination of the bladder together with cytologic examination for malignant 
cells in the urine. Cystoscopy is an unpleasant invasive procedure and has certain side effects. 
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Voided urinary cytology (VUC) remains the method of choice for the non-invasive detection 
of BCa, but it is complex and lacks of sensitivity and accuracy.  
 
While a number of biomarkers identified for BCa diagnosis may have utility in solid tissue or 
patients’ serum, urine-based assays have obvious advantages for the detection of urological 
cancers, specifically BCa. Most importantly, urine is available for collection non-invasively. 
In addition, the ease of the collection of urine ensures patient compliance and allows for 
copious sample collection and repeat sampling. Based on the previous studies by Dr. Rosser 
and his colleagues,67, 69-78 a 14-protein multiplex diagnostic signature has been revealed. 10 of 
the 14 proteins associated with the diagnostic signature have been validated by ELISA. Thus 
the development of a non-invasive high-throughput urine-based assay using reliable 
diagnostic markers would be of tremendous benefit to both patients and the healthcare 
system. 
 
Dr. Rosser’s group has rich experience on validation urine-based bladder cancer biomarkers. 
By cooperating with Dr. Rosser’s group, 3 of 10 well-validated BCa related biomarkers were 
chosen as representatives for testing the feasibility of our strips in this section. Here we 
designed and developed a LFS of sandwich format for qualitative analysis of three BCa 
related biomarkers (Creatinine, Matrix metallopeptidase 9 (MMP-9) and vascular endothelial 
growth factor (VEGF)) in standard solutions as well as in urine samples from ten patients 
who potential with bladder cancer. The reliability of the sensor was further investigated by 
comparing the results to those of commercially available ELISA kits did by Dr. Rosser’s 
group. The strips could provide a potential approach for simple and fast qualitative detection 
of these three biomarkers in urine samples. 
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3.1.2. Experimental 
3.1.2.1. Materials and Apparatus 
Sheep polyclonal to Creatinine antibody (US Biological (Salem, MA)). Rabbit polyclonal 
secondary antibody to Mouse IgG and Rabbit polyclonal secondary antibody to Sheep IgG 
(Abcam (Cambridge, MA)). Human Total MMP-9 DuoSet and Human VEGF DuoSet (R&D 
Systems, Inc. (Minneapolis, MN)). Glass fiber, nitrocellulose membrane, absorbent materials 
and polyester backing materials (Millipore (Billerica, MA)). Sucrose, Tween® 20 
(polyoxyethylene-20-sorbitan monolaurate) and Tris.HCl (1 M) (Fisher Scientific (Fairlawn, 
NJ)). Creatinine standard solution, Bovine serum albumin (powder), Sodium chloride (NaCl), 
Sodium phosphate (Na3PO4), Gold chloride trihydrate (HAuCl4 .3H2O) and Potassium 
carbonate (K2CO3) (Sigma-Aldrich (St. Louis, MO)). Triton X-100, Tri-Sodium Citrate 
Dihydrate, Phosphate buffered saline (PBS, 1X, pH=7.4) and Drying Oven (VWR (West 
Chester, PA)). Dispenser Linomat 5 was from CAMAG (Wilmington, NC) and Zetasizer was 
from Malvern Instruments, Woodstock, GA. Canon T1i camara was bought from Canon, JP. 
 
3.1.2.2. Fabrication of LFS 
General procedures found in section 2.2. 
 
3.1.2.3. Preparation of standard solution and urine samples 
General procedures found in section 2.3.1. 
 
3.1.2.4. Strip assay 
General procedures found in section 2.4. 
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3.1.3. Results and discussion 
3.1.3.1. Principle of the cancer biomarkers detection by LFS 
The principle of the immuno strip is based on the specific immunoreactions occurring 
between the antibodies and cancer biomarkers and is illustrated in Figure 3.1. In this section, 
we choose the sandwich type design (Figure 3.1a) for all three biomarkers, given that the 
biomarkers described contain multiple antigenic binding sites (section 2.5.1) 
 
As shown in Figure 3.1b, two clear lines on the membrane is a positive result (+). A single 
line in the control zone is a negative result (-). However, false positive and negative response 
will be given by the immunostrip in some conditions. For example, the pH of the gold 
nanoparticle solution and the concentration of the antibody are very important for efficient 
conjugation. Non-specific binding between the antibodies on the test line and the gold 
nanoparticles from conjugation pad due to inefficient conjugates will lead to false positive 
response. In addition, correct antibody pair is another important factor for accurate 
immunostrip response. After interacting with the antibody in the conjugation pad, the analyte 
still can be captured by the antibody on the test line through another antigenic site, avoiding 
the false negative responses. The conditions of the running buffer (i.e. salts, pH) which affect 
the binding efficiency between the antigen and antibody could also cause false negative 
response. So optimization of the fabrication condition is very crucial for the accurate 
immunostrip response. 
 
 
35 
 
 
Figure 3.1. (a) Schematic Drawings for the principle of sandwich type lateral flow strips 
based on gold nanoparticles and (b) the structure of a strip together with the illustrations for 
testing results. 
 
3.1.3.2. Individual biomarker detection by standard samples (Creatinine/MMP-9/VEGF) 
In order to demonstrate the feasibility of the device, first, we used a standard solution of each 
individual biomarker with high concentration. 100 μL Standard sample with available 
concentration (Creatinine: 30 μg/mL; MMP-9: 50 ng/mL; VEGF: 120 ng/mL) were applied 
to the strips separately, and photographs were taken by digital camera after 10 min. 
 
Figure 3.2 shows the typical responses of the strips to the three biomarkers with presented 
concentrations. As these are intended to be single-use strips, each sample was tested in 
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triplicate to ensure the repeatability and reliability of the results. From figure 3.2, we can see 
that there is only one red line (Control line) after applying the blank sample to the strip, 
containing no biomarker. While, apparently, there are two lines, both test and control lines, 
appeared by using standard solutions without exception. The results indicate that the device 
could be used as an analytical platform for individual biomarker detection.  
 
 
Figure 3.2. Typical responses of the strips to three biomarkers. Top: Blank samples without 
any biomarker; Below: Standard samples with individual biomarker (Creatinine: 30 μg/mL; 
MMP-9: 50 ng/mL; VEGF: 120 ng/mL). 
 
3.1.3.3. Individual biomarker detection using urine samples 
After confirming the feasibility of the strips for these biomarkers detection, it then can be 
used for the clinical urine sample testing. 10 urine samples potentially with bladder cancer 
(No. 0087, 0129, 1057, 1150, 0130, 0054, 0110, 0781-2, 0212, and 0403) obtained from Dr. 
Rosser’s Translational Research Laboratory were applied to the strips following the same 
method for the standard solution. After 10 min, photographs were taken by using digital 
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camera. Figure 3.3 displays the representative responses of the strips (three types) to these 
urine samples. Each individual image was a representative image from the triplicate results. 
 
 
Figure 3.3. Representative results of strips (three types) to 10 clinical urine samples. 
 
As shown in Figure 3.3, some of the strips present only one red line (control line), while, the 
rest give two lines (both test and control line) in the reaction window. Take No. 0087 as an 
example, there are two lines in Creatinine strips and one line in both MMP-9 and VEGF 
strips, indicating that No. 0087 only contains detectable amount of Creatinine. In the same 
way, we can conclude that No. 1150 contains detectable amounts of all three biomarkers 
according to our device. Further, follow the same analysis, we marked “+” as the sample 
contains certain biomarker, while “-” if it doesn’t, which are summarized in Table 3.1. Table 
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3.1 gives a clearer and more straightforward idea of the situation of samples compared with 
the image. 
 
Table 3.1. Summary of the results of the urine samples with +/-. Positive (+) represents that 
the sample contains certain biomarker, while negative (-) represents that the sample doesn’t 
contain this biomarker. 
 
 
Table 3.1 also gives combination result of the multiplex biomarkers to some extent. The level 
of only a single biomarker in any biological samples may not be able to provide a reliable 
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diagnostic conclusion. The ability to detect and quantify several biomarkers simultaneously 
in the same sample via a semi-robust multiplexed assay will reduce the assay costs and 
improve efficiency. A concept graph is illustrated in Figure 3.4.  In addition to BCa diagnosis, 
comprehensive tests for the levels of multiplex biomarkers will also help us to better 
understand the underlying physiology of BCa and to monitor the BCa treatment progress. 
 
 
Figure 3.4. Illustration of a BarCode based multiplex detection devices. 
 
In theory, multiple biomarkers could be tested simultaneously on a single test strip simply by 
pre-coating regions with multiple chemical and/or immunological reactants. However, 
practically, this approach is hampered by the increased likelihood of misinterpreting results 
when multiple lines are to be inspected. In addition, the difficulty of fabricating the test strips 
in which no two lines appreciably overlap will be another major practical concern.  At this 
stage, we tested these biomarkers separately by using a single functional strip. However, we 
can perform a multiplex analysis by using a format as Table 3.1. 
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3.1.3.4. Comparison of the results of strips to those of the commercial ELISA kits 
The efficacy of the novel strips to accurately detect BCa was further investigated by 
comparing the results to those obtained from commercial available ELISA kits. These ELISA 
assays are performed according to manufacturer recommendation. Briefly, standards or urine 
samples were added in triplicate to 96 well plates directed at a specific biomarker, followed 
by the addition of biotinylated antibody.  The absorbance values were read on a microplate 
reader (Bio-tek, SynergyTM HT, VT) at a wavelength determined by the manufacturer.  The 
above was repeated for each of the three biomarkers.  For each biomarker, a standard curve 
was prepared using purified standards for each protein assessed.  Signal intensities of each 
biomarker were converted to concentration values by reference to the standard curve.  
 
Previous statistics (Median (min, max)/Mean +/- SD) from urine samples (127 subjects: 64 
subjects with BCa and 63 subjects without a BCa) did by Dr. Rosser’s group show: 0.9 (0, 
1002)/46 +/- 141 ng mL-1 for cancer subjects and 0 (0, 14.25)/0.35 +/- 1.81 ng mL-1 for 
healthy subjects (MMP-9); 333 (0, 9814)/835 +/- 1725 pg mL-1 for cancer subjects and 0 (0, 
904)/66 +/- 194 pg mL-1 for healthy subjects (VEGF), giving a general idea of the clinical 
range of these biomarkers in urine. Based on these statistic data, we defined a value over a 
certain threshold as positive (+), with which we can transfer the digital value obtained from 
the ELISA kit into positive (+)/negative (-) style which is similar to Table 1. At the end, we 
concluded a consistency testing form of the two methods (see Figure 3.5). From Figure 3.5, 
we can find that the consistency of the results is very high for all three biomarkers 
(Creatinine: 90%; MMP-9: 80%~100%; VEGF: 90%). The test strip provides a simple, low 
cost and portable platform for BCa related biomarker detection and could potentially be used 
as a screening tool for BCa through multiple diagnostic markers in future. 
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Figure 3.5. Consistency of the results obtained from strips and ELISA. Red circle: data got 
from ELISA kits is in agreement with LFS (Table 3.1); Blue circle: inconclusive; None: the 
data obtained from ELISA kits is disagreement with that in Table 3.1. 
 
3.1.4. Conclusions 
We demonstrate here a novel POCT device in LFS format that provides a rapid qualitative 
measurement of three BCa-related biomarkers (Creatinine, MMP-9 and VEGF) in both 
standard solutions and clinical urine samples for the very first time. The diagnostic signature 
given by the strips can be further developed into a combination result in the near future. This 
kind of comprehensive test for the levels of multiplex biomarkers will help us to better 
understand the underlying physiology of BCa and to monitor the BCa treatment progress in 
addition to BCa diagnosis. In the end, by comparing the results obtained from the novel strips 
to those of the commercial ELISA kits, we can conclude that the strips can provide a useful 
tool for quick and non-invasive BCa diagnostic. 
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3.2. Development of LFS for an oxidative DNA damage biomarker detection 
3.2.1. Introduction  
In the previous section, we developed a LFS for colorimetrical detection of three BCa-related 
biomarkers. The qualitative assay is simple and fast, demonstrating that a feasible and 
reliable platform of LFS was established for our own applications. Nevertheless, in most 
cases, quantitative information is still necessary and important for analyzing the 
concentration of the target. In this section, an image processing program “ImageJ” was used 
for further quantitative analysis of the colorimetrical results of the LFS. A DNA oxidative 
damage biomarker, 8-OHdG was used as a model to demonstrate the concept, and the strip 
can also be used as a useful screening tool for nanotoxicity assessment. 
 
In living cells endogenous reactive oxygen species (ROS) are produced as a result of various 
physiological processes, metabolic and other biochemical reactions. ROS, at low 
concentrations can serve as signaling molecules, necessary for the normal cellular activities. 
However, an increase in the level of ROS from exogenous sources such as ultraviolet or 
ionizing radiation, cigarette smoking, hazardous chemicals, etc.79 can lead to an abnormal 
oxidant system called oxidative stress.80 In the presence of oxidative stress, ROS generated in 
vivo can cause extensive oxidative damage to biomolecules. DNA is a particularly important 
target for oxidation, as damage may lead to heritable alternations. It is well known that the 
study of oxidative DNA damage is clinically important.80 Numerous studies have shown that 
oxidative DNA damage links pathogenically to a variety of aging-associated degenerative 
diseases such as cancer, coronary heart disease and diabetes.81  
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Among the four constituent bases of DNA, guanine in particular is the most readily oxidized. 
Upon oxidation, a hydroxyl group is added to the C-8 position of deoxyguanosine in DNA,82 
resulting in the production of 8-hydroxy-2’-deoxyguanosine (8-OHdG), one of the 
predominant forms of free radical-induced lesions of DNA. 8-OHdG is probably the most 
studied oxidative DNA damage product due to its relative ease of measurement and pre-
mutagenic potential.83-86 Evidence shows that 8-OHdG can give rise to G-to-T transversion 
mutations in key genes known to be involved in the development of cancer,87 so, elevated 8-
OHdG levels have been noted in numerous tumors84, 85 and thus is widely used as a 
biomarker for oxidative stress and carcinogenesis. 88-90 Urinary 8-OHdG, in particular, has 
been measured most frequently to indicate the extent of oxidative damage because it is 
noninvasive and technically less involved. 
 
The traditional methods for 8-OHdG quantitative analysis are high-performance liquid 
chromatography (HPLC) with electrochemical detection (ECD),91, 92 gas chromatography-
mass spectrometry (GC-MS),93 HPLC tandem mass spectrometry,94, 95 and Enzyme-linked 
Immunosorbent Assay (ELISA).96 These methods have been successfully used to analyze 8-
OHdG in cell lysates, fluid samples and organs. However, these are lab based techniques 
requiring costly and cumbersome equipment and trained personal to perform the 
measurements. Thus, these techniques are of limited use in close proximity to patients. There 
is a great need for a portable POCT device for use by the mass public for easily available 
biological samples such as urine, saliva, blood, etc.97 An ideal POCT device would serve the 
purpose of rapid and accurate detection of 8-OHdG with a user friendly operation eliminating 
the need for lab facilities and professionals.98 This POCT device would provide results in 
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minutes rather than days or weeks and eliminate the concerns involved with the transport and 
storage of biological samples.  
 
Significant progress in nanotechnology has had a measurable impact on industrial technology. 
However, the increased utilization of nanomaterials may negatively affect human health and 
the environment.99-101 Oxidative stress is one of the most discussed mechanisms regarding the 
negative effects of nanomaterials on human health. Many studies83, 84, 102-109 have shown that 
some metal oxide nanoparticles can cause ROS generation that leads to oxidative stress and 
DNA damage in the body. Therefore, characterization and reliable toxicity screening tools 
are required for new and existing nanomaterials, ensuring their compatibility for medical 
applications and for the safety of the environment.  There are a number of different 
approaches that can be taken to assess the toxic effects of NPs, which can be categorized into 
three classes based on their objects of measurement. 1. Cell proliferation/viability assay, 
which is also called cytotoxicity measurement in other publications, includes Trypan Blue 
assay,102, 110-113 Alamar Blue assay,102, 111, 114 Neutral Red assay,115, 116 lactate dehydrogenase 
(LDH) assay,102, 110, 111, 117-120 Formazan-based assays (MTT, MTS, WST),102, 110, 111, 115-117, 119, 
120 and clonogenic assay.102, 110, 111 2. Direct or indirect intracellular ROS measurement, such 
as lipid peroxidation measurement,102, 110, 111, 114, 121 glutathione (GSH) assay,102, 111, 114-116, 119, 
122 Electroparamagnetic resonance (EPR) assay,111, 112 and 2, 7-dichlorofluorescin (DCFH) 
assay102, 111-116, 119, 122 3. Assays on the genomic level, like Comet assay,102, 110-113, 116, 118, 120, 123 
and DNA damage biomarker assay.110, 112, 124  
 
In this section, we designed and developed a novel LFS for quantitative 8-OHdG detection 
for the very first time. The feasibility of the strip was first evaluated by testing 8-OHdG in 
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standard solutions.  Afterwards, the strip was used to measure 8-OHdG concentrations in cell 
model (rat epithelial cells (CCL-149)) to assess the nanotoxicity (in respect of oxidative 
stress) of three particles (CuO, TiO2 and CdO) in vitro on the genomic level. One of the most 
apparent pathways for NPs caused sickness or organ dysfunction is through prolonged 
inhalation exposure. Lung function changes have been reported after prolonged inhalation 
exposure to multiple NPs. Because of this, lung epithelial cells are the most physiologically 
relevant in vitro model to study nanotoxicity. Rat epithelia cell line has been widely used as a 
model110, 125-129 to study nanotoxicity or cellular oxidative stress, therefore, CCL-149 was 
used as the cell model in this study. At the end, we compared the results obtained from strips 
to those from Alamar Blue assay and Electrical impedance sensing (EIS) system to 
demonstrate the reliability of our strips for nanotoxocity assessment. In conclusion, the novel 
strip we developed can potentially provide a portable sensing system for rapid 8-OHdG 
measurement in readily available biosamples, which also can be further used as a screening 
tool for nanotoxicological investigations. 
 
3.2.2. Experimental 
3.2.2.1. Materials 
PBS (1X, PH=7.4), Triton X-100 and Tri-Sodium Citrate Dihydrate (VWR (West Chester, 
PA)). Gold chloride trihydrate (HAuCl4 •3H2O), Bovine serum albumin (powder), Sodium 
borohydride (NaBH4), Sodium periodate (NaIO4), Ethylene Glycol, Potassium carbonate 
(K2CO3), Sodium phosphate (Na3PO4), Sodium chloride (NaCl), Copper oxide (CuO), 
Cadmium oxide (CdO) and Titanium dioxide (TiO2) (Sigma-Aldrich (St. Louis, MO)). 
Tween® 20 (polyoxyethylene-20-sorbitan monolaurate), Sucrose and Tris–HCl (1 M) (Fisher 
Scientific (Fairlawn, NJ)). Plastic backing, Nitrocellulose membrane, Absorbing pad and 
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cellulose paper (Millipore (Billerica, MA)). 8-hydroxy-2-deoxy Guanosine and 8-hydroxy 
Guanosine (Cayman chemical (Ann Arbor, MI)). Mouse monoclonal antibodies to 8 
hydroxyguanosine and polyclonal Goat anti Mouse IgG (Abcam (Cambridge, MA)). Alamar 
Blue, DMEM, fetal bovine serum, and penicillin–streptomycin (Invitrogen (Merelbeke, 
Belgium)). Rattus epithelial cells, CCL-149 was from ATCC (Manassas, VA). 
 
3.2.2.2. Equipment 
HP Scanjet G3110 Photo Scanner (Hewlett-Packard, Palo Alto, CA). Zetasizer (Malvern 
Instruments, Woodstock, GA). Drying Oven (VWR (West Chester, PA)). Dispenser Linomat 
5 (CAMAG (Wilmington, NC)). ImageJ (http://imagej.nih.gov/ij/download.html) was 
downloaded from the internet. 
 
3.2.2.3. Fabrication of AuNPs-based competitive LFS 
General procedures found in section 2.2. 
 
3.2.2.4. Preparation of standard solution and samples 
General procedures found in section 2.3.2 
 
3.2.2.5. Particle source and characterization 
TiO2-NPs (∅ < 25 nm) and CuO-NPs (∅ < 50 nm) were obtained in powder form from 
Sigma-Aldrich. The dry powder of NPs was suspended in deionized water (1 mg mL-1) and 
cell culture medium (1 mg mL-1) respectively, and then sonicated using a sonicator bath at 
room temperature for 20 min (120 V/50-60 HZ) to form a homogeneous suspension. For size 
measurement, sonicated NPs stock solutions (1 mg mL-1) were then diluted to working 
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solutions (100 μg mL-1). TEM was used to characterize the size and shape of the NPs. A drop 
of aqueous NPs suspension was placed onto a carbon-coated copper grid, air-dried and 
observed with TEM (2000FX, JEOL). DLS was used to determine the hydrodynamic size 
and zeta potential of the NPs suspension both in the DI water and culture medium.  
 
3.2.2.6. Cell culture and NPs solution preparation 
Rat epithelial cells (CCL-149) were obtained from ATCC and cultured in DMEM/F-12 
medium supplemented with FBS (10%) and penicillin-streptomycin (5%) at 5% CO2 and 37 
°C. At confluence, cells were harvested using trypsin (0.25%) and sub-cultured into 12-well 
plates (106 cells per well), 24-well plates (5×104 cells per well) or EIS chips (6×104 cells 
per well) according to the selection of experiments. Cells were allowed to attach the surface 
for 24 h prior to NPs treatment, and cells not exposed to NPs served as controls in each 
experiment. CuO, CdO and TiO2 NPs were suspended in cell culture medium and diluted to 
the same concentration (100 μg mL-1). The appropriate dilutions of NPs were then sonicated 
using a sonicator bath at room temperature for 20 min (120 V/50-60 HZ) to avoid NPs 
agglomeration prior to administration to the cells.  
 
3.2.2.7. Assays on nanoparticles-induced toxicity assessment in cells 
3.2.2.7.1. Cellular oxidative stress assessment from 8-OHdG concentrations by strips 
Cells were seeded in 12-well plates with 106 cells per well. After 24 h of cell attachment, 
prepared NPs solutions were added to the corresponding wells with a final concentration of 
100 μg mL-1. In order to investigate the overall oxidative stress induced by NPs in cells, 
concentrations of 8-OhdG both in the cell culture medium and within the cells after NPs 
exposure (12 h) were tested by the LFS. First, the cell culture medium of different 
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experimental groups were collected at the end of exposure time (12 h) by pipets and put in 
tubes. After centrifugation (2900 rpm or 1000 xg, 5 min), the supernants were collected and 
marked as “cell culture media sample” for following strip test. Second, the cells left in the 
wells and pellets in the tubes after previous centriguation were resuspended and lysed by cell 
lysis buffer containing Tris (20 mM, pH=8.0), NaCl (137 mM), Triton X-100 (1%), Glycerol 
(10%) and EDTA (5 mM). The cell lysates were obtained by collecting the supernant of the 
mixture after centrifugation (2900 rpm or 1000 xg, 5 min) and marked as “cell lysates sample” 
for following strip test. Strip test procedures performed as outlined in section 2.4. 
 
3.2.2.7.2. Alamar Blue assay 
Cells were seeded in 24-well plates with 5×104 cells per well. One day later (24 h) and at 
time point 0, medium or medium containing NPs (100 μg mL-1, final) were added on top of 
cells. Since incubation of Alamar Blue takes 6 hours, the reagent of 10 % sample volume was 
added at time point -6, 0, and 6 hours. Thus measurement of net absorbance at 570 nm was 
carried at time point 0, 6, and 12 hours. All data points were subtracted by reference number 
which came from the reading of the mixture of medium and Alamar Blue only, and then 
normalized to the average of triplicates at time point 0. 
 
3.2.2.7.3. Cytotoxicity assay by Electrical Impedance Sensing (EIS) System 
Cell suspension (0.6 mL, 6×104 cells) was applied into each well in the EIS chip for the 
experiments. After 24 h of cell attachment, prepared NPs solutions (100 µL) were added to 
the corresponding wells with a final concentration of 100 μg mL-1.  The resistance changes 
produced by the attachment of cells to the electrodes were monitored over a 36 h time period 
(both before and after NPs addition). The EIS chip design was previously reported. 125  In 
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short, as cells are placed in each well of the chip, they settle down onto the electrode surface 
creating a barrier for the flowing current increasing the resistance measurements. Thus, it is 
possible to monitor the cell attachment and proliferation from the change in resistance 
measurements. 
 
3.2.3. Results and discussion 
3.2.3.1. Principle of 8-OHdG detection by LFS 
The principle of the immuno strip based on the specific immunoreactions occurring between 
the antibodies and the DNA damage biomarker (8-OHdG) is illustrated in Figure 3.6. 
Competitive format was chosen in this section for 8-OHdG testing, as this small molecule 
contains a single antigenic binding site, which cannot bind to two antibodies simultaneously 
(2.5.2).  
 
 
Figure 3.6 Mechanism of competitive LFS for 8-OHdG testing 
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3.2.3.2. Quantitative analysis by using Software ImageJ 
A series of 8-OHdG standard solutions with concentrations of 0, 0.1, 1, 10, 50, 100, 500, 
1000, 10,000 and 100,000 ng mL-1 in 1X PBS buffer were prepared and applied to the strips. 
After 10 min, photographs were taken by using a digital camera, then software ImageJ130 was 
used for the quantitative analysis. 
 
Figure 3.7 shows the typical responses of the test strip to 8-OHdG with increasing 
concentrations from 0 to 100,000 ng mL-1 dissolved in 1X PBS. The color intensity of the test 
line deceased when the sample concentration increased in general, which was consistent with 
the theory of detection of competitive format. The visual detection limit is defined herein as 
the minimum target analyte concentration required by the test line (T-line) for showing no 
obvious staining effect. Following this definition, the visual detection limit achieved by the 
standard sample is above 1000 ng mL-1. The visual detection range is from 0 to 10,000 ng 
mL-1. 
 
 
Figure 3.7. Typical responses of the competitive AuNPs based test strips to different 
concentrations of 8-OHdG; Top line: Test-line; Bottom line: Control-line. The concentration 
unit for those shown on the bottom is ng mL-1. 
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In order to quantitatively extract the detection limit and detection range of this method, the 
test strips were further subjected to optical density analysis. The signals from both the T-line 
averaged from three parallel runs, and one from red color tape (reference) were digitized to 
optical density using software of ImageJ and expressed by the integral area of the cross-
section of the T-line (areaT) and reference-line (areaR) within a fixed peak width. In order to 
eliminate the influence of artificial effects caused by camera (i.e. lighting, distance, etc.), a 
relative optical density (ROD) defined as areaT/areaR was used in the signal analysis. The 
optical density profiles of both the T-line and C-line recorded under different analyte 
concentrations are shown in Figure 3.8 with the optical densities of the T-line and C-line 
being normalized with respect to that of baseline. The optical intensity of the T-line quite 
obviously increased with the decrease of the analyte concentration. The discrimination of 
intensities is more intuitive compared to the photograph. 
 
 
Figure 3.8. Optical density profiles of the T-line and C-line recorded by using software 
ImageJ and Sigmaplot after running a series of standard solutions with different 8-OHdG 
concentrations dissolved in 1X PBS. 
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After optical density analysis, we can get a representative calibration curve of 8-OHdG as 
shown in Figure 3.9. A normalized intensity (NI) defined as ROD/ABD (average blank 
density) of the T-line was used as the y-axis, concentration of 8-OHdG was used as the x-axis. 
As these are intended to be single-use strips, each data point represents the average response 
from three strips and the error bars represent the standard deviation. With the definition of the 
detection limit as the minimum concentration of analyte required for inducing a 10% NI 
decrease, it was determined as 0.9 ng mL-1 for standard sample.  
 
 
Figure 3.9 Dose-response curves for 8-OHdG based on optical density analysis using 
standard samples. Values are mean ± SD from three independent experiments. 
 
3.2.3.3. Nanomaterials induce oxidative stress assessment in cells 
3.2.3.3.1. Characterization of toxic NPs 
The primary sizes of the NPs were determined using Transmission electron microscopy 
(TEM). As shown in Figure 3.10, the size of nano-TiO2 was about 20 ± 5 nm (a). The nano-
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CuO had the size of about 50 nm (b). The size was consistent with the data specified by the 
manufacturer. 
 
 
Figure 3.10 Size of NPs observed by TEM. (a) Left: the size of TiO2-NPs was about 20 ± 5 
nm and bar scale is 100 nm and (b) Right: the size of CuO-NPs was about 50 nm and bar 
scale is 100 nm. 
 
Furthermore, dynamic light scattering (DLS) technique was used to characterize the behavior 
of the NPs, and the hydrodynamic sizes and surface charges were measured using a Zetasizer 
in a biological environment (i.e., DMEM cell culture medium). The NPs were suspended in 
deionized water or DMEM for analysis of their agglomerate sizes and zeta potential. Zeta 
potential measurements revealed that TiO2-NP had the surface charge ranging from -10.5 ±  
0.6 mV (n = 3) (in medium) to -15 ± 1.1 mV (n = 3)  (in water), and the average particle 
hydrodynamic diameter ranged from 574 nm (PDI = 0.551) (in medium) to 1510 nm (PDI = 
0.492) (in water). CuO-NPs demonstrated mean agglomerate sizes ranging from 338 (PDI = 
0.346) (in medium) to 1350 nm (PDI = 0.312) (in water), and the surface charge ranged from 
-12.5 ± 0.5 mV (n = 3) (in medium) to -6 mV ± 0.2 (n = 3) (in water). These differences in 
zeta potential of TiO2 and CuO-NPs can influence particle uptake as well as toxicological 
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parameters like ROS generation and genomic damage. Particle size observed by DLS did not 
coincide with the results obtained from the TEM. The larger size of the NPs in the 
hydrodynamic state compared to the size obtained by the TEM might be due to the tendency 
of the NPs to aggregate in aqueous state. This finding is supported by other investigators.119, 
131, 132 
 
The three metal oxides used in this study are relevant NPs types and are in widespread use in 
a number of consumer products. CuO NPs are utilized in various applications such as 
industrial catalysts, semiconductor devices, antimicrobial preparations, heat transfer fluids, 
and cosmetics.114, 133-135 TiO2 NPs have excellent optical performance and electrical 
properties and are produced for applications in paints and coatings and also in cosmetics as 
UV-absorbers. CdO can be used in batteries, electroplating baths, pigments, plastics, catalyst, 
ceramic glazes, synthetic products, and a variety of other materials.136 Nevertheless, many 
studies112-116, 119-121, 137 have demonstrated that these metal oxide NPs can induce cytotoxicity 
and DNA damage. Thus, they have been selected here as models for nanotoxicity assessment. 
 
3.2.3.3.2. Effects of NPs on 8-OHdG level as a biomarker of oxidative stress in cells 
A series of 8-OHdG solutions with concentrations of 0, 1, 10, 20, 40 and 80 ng mL-1, both in 
cell lysis buffer and cell culture medium (DMEM), were prepared and applied to the strips. 
“Cell lysates sample” and “cell culture media sample” obtained in section 3.2.2.7.1 were also 
applied to the strips. After 10 min, photographs were taken by using a photo scanner (Figure 
3.11), and then software ImageJ was used for the quantitative analysis. Figure 3.11 (a) and 
(c) show that the optical intensity decreased obviously when the concentration of 8-OHdG 
increased, both in the cell lysis buffer and in the cell culture medium, which is still consistent 
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with the mechanism of the competitive format and can be used as a calibration standard. 
Figure 3.11 (b) and (d) demonstrate the results by using different NPs, in which the color 
intensities of all the three experimental groups (NPs) are slightly lighter compared to the 
control indicating that these metallic NPs can lead to more 8-OHdG generation. Among the 
three experimental groups, CuO NPs seemed to cause most oxidative damage in cells with 
highest 8-OHdG generation in both the cell lysate and the cell culture medium. 
 
 
Figure 3.11 The photographs of test line based on 8-OHdG samples dissolved in cell lysis 
buffer (a) and cell culture medium (c); the photographs of test line based on cell lysate (b) 
and culture medium (d) after cells were treated with NPs solutions. The concentration unit for 
those shown in the middle is ng mL-1. 
 
Figure 3.12 illustrates the linear fitting curves for 8-OHdG both in the cell lysis buffer (a) and 
the cell culture media (b) with correlation coefficients of 0.957 and 0.9632, respectively. 8-
OHdG concentrations in the three experimental groups can be estimated by these two curves 
(n = 6) presented in Figure 3.13. The CuO groups, both in the cell lysate (a) and the cell 
culture medium (b), have the highest 8-OHdG concentrations (23.24 ± 2.65 and 13.78 ± 1.04 
ng mL-1, respectively), followed by the CdO groups (12.35 ± 1.42 and 8.43 ± 0.68 ng mL-1, 
respectively). While TiO2 (1.76 ± 0.19 and 2.86 ± 0.14 ng mL-1, respectively) shows no 
toxicity effect on oxidative stress in cells with similar 8-OHdG concentrations compared to 
the control (2.17 ± 0.15 and 2.56 ± 0.18 ng mL-1, respectively).  
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Figure 3.12 Calibration curves for 8-OHdG both in cell lysis buffer (a) and cell culture media 
(b). Values are mean ± SD from three independent experiments. ROD’: ROD (relative optical 
density)/ ABD (average blank density)). 
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Figure 3.13 Estimated 8-OHdG concentrations in cell lysate (a) and in cell culture media (b) 
after cell were exposed to different NPs solutions.  
 
3.2.3.3.3. Cytotoxicity study of NPs by Alamar Blue assay 
Although nanotoxicity of these three particles choosen have been studied individually or in 
combination, we still need to characterize their toxic effects simultaneously in our rat 
epithelial cell model by a well established method, which can serve as the reference for our 
newly developed detection method. Thus, Alamar Blue assay in a time course manner was 
carried out with or without the presence of NPs (Figure 3.14) in this section to validate the 
results of strips obtained in the previous section . At time point 0 h while NPs were absent in 
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the medium during the Alamar Blue incubation phase, four groups exhibited nearly no 
difference in cell metabolic activity. At the range from 0 h to 12 h, control (no NPs) and TiO2 
showed normal cell growth and increased total metabolic activity, which was consistent with 
many other studies stating TiO2 with a similar size had limited cytotoxicity. Nevertheless, the 
other NPs CuO and CdO prevented the normal cell growth. Even at the point 6 hours after 
adding NPs, the total metabolic activity falled by 40% around in both settings.  
 
 
Figure 3.14 Alamar Blue assay for CuO, CdO and TiO2 on CCL-149 (n = 6). Lines A 
represent the Cells only (cells with medium only).  CuO (line B), CdO (line C) and TiO2 (line 
D) are added at the initial time point.  
 
3.2.3.3.4. Cytotoxicity study of NPs by Electrical Impedance Sensing (EIS) system 
The whole cell based EIS system, previously published by our lab125, was also applied to 
determine the cytotoxiciy of CuO, CdO, and TiO2 NPs on rat epithelial cells (CCL-149). The 
EIS system measures the resistance produced by growing cell monolayers over electrodes 
and can detect changes in resistance that may occur with cell density changes in the cell layer 
after NPs exposure, and thus provides a kinetic monitor of cell viability. In this section, the 
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three NPs (CuO, CdO and TiO2) (100 ug mL-1) were added to the wells after 24 h of cell 
attachment, and the resistance changes produced by the attachment of cells to the electrodes 
were monitored over a 36 h time period.  This setup would provide the kinetics of the 
interactions of the NPs with the cells. 
 
Figure 3.15 illustrates the resistance readings for five different settings: Blank (medium 
only), CuO-24 hrs (CuO, 50 nm, 100 µg mL-1, added after 24 hours of cell attachment), CdO-
24 hrs (CdO, 100 µg mL-1, added after 24 hours of cell attachment), TiO2-24 hrs (TiO2, 20±5 
nm, 100 µg mL-1, added after 24 hours of cell attachment) and a control of cells only (mouse 
epithelial cells, CCL-149). As shown in Figure 3.15, resistances in all five groups increased 
within the first 24 h with more and more cells attaching to the surface of electrodes before 
adding NPs. Nevertheless, upon inoculation of the NPs after 24 h, the trends became 
extremely different. Once the CuO was added to the cells (Line B), we observed a rapid 
decrease in the resistance values measured, eventually returning to readings similar to the 
blank (Line E), indicating cell detachment and the harsh cytotoxic effect of CuO towards the 
CCL-149, and being consistant with the results onbtained by our strips and Alamar Blue 
assay. The cytotoxic measurements of TiO2 NPs towards the CCL-149 (Line D) showed 
slight difference in resistance values to those observed for the control (Line A). From this 
observation, it is evident that TiO2 NPs (25 nm) have fewer cytotoxic effects on the cells 
compared to the CuO NPs (50 nm) with the same concentration (100 ug mL-1) and similar 
size, which is also comparable with the results got from our strips and Alamar Blue assay. 
When cells were exposed to CdO, noticeable changes in resistance (Line C) were observed 
compared to the control (Line A), which is consistent with the fact that it is extremely toxic 
and affects the growth mechanism of the cells given by Alamar Blue assay. CdO was used 
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here as a negative control and employed to demonstrate the ability of the EIS system. 
Cadmium is a toxic material that has been shown to cause lysosomal damage and DNA 
breakage in mammalian cells and disrupt mitochondrial function and promote apoptosis.137 
However, the value decreased slowly compared to the CuO NPs (Line B), indicating a slower 
detachment rate of the cells. The observed phenomena may be attributed to the fact that the 
smaller NPs (CuO, 50 nm) can enter the cell and damage the cells more easily. 
 
 
Figure 3.15 Resistance readings for CuO, CdO and TiO2 on CCL-149. Lines A and E 
represent the Cells only (cells with medium only) and Blank (medium only) resistance 
readings.  CuO (line B), CdO (line C) and TiO2 (line D) are added after 24 hours of cell 
attachment. 
 
Comparing the above sections, we notice that the high toxicity of CuO NPs leads to almost 
100% cell detachment within 2 h after NPs addition (Figure 3.15, line B), which could be a 
response to the DNA damage (illustrated in Figure 3.13, CuO NPs induce the highest 8-
OhdG generation in cell) as a way to prevent a mutagenic outcome. It is also possible that 
DNA damage to some extent is a consequence of cytotoxicity. However, from the present 
data, it is hard to clarify which process is the driving force. On the other hand, the TiO2 NPs 
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cause cytotoxic effects (Figure 3.15, line D), however, without apparent increase in 8-OHdG 
levels, indicating different mechanisms underlying these effects. 
 
The results show that there was a high variation among different NPs with similar size and 
concentration regarding their ability to cause cytotoxicity and DNA oxidative lesions. Results 
from Alamar Blue Assay and EIS system were generally consistent with those from our 
strips, indicating that the test strip can be served as a simple and low cost alternative method 
for oxidative stress assessment in cells. 
 
3.2.4. Conclusions 
In this work, we successfully designed and presented a novel LFS for an oxidative DNA 
damage biomarker (8-OHdG) detection. Besides an instant eye-based qualitative detection, a 
quantitative analysis was also obtained through an image processing program “ImageJ”. The 
detection is quite quick (~10 minutes) and of high sensitivity (as low as 0.9 ng mL-1, which is 
comparable to that of commercialized ELISA kit). By using the same strip, we further 
assessed the nanotoxicity of three metal oxides (CuO, TiO2, CdO) NPs on rat epithelial cells 
(CCL-149) through measuring 8-OHdG concentrations produced in cells after NPs exposure. 
Feasibility of this method was validated by the comparison with two other established 
methods, Alamar Blue assay and EIS system on the level of cell proliferation/viability. In 
conclusion, the strip can provide a useful platform for quantitative or qualitative 8-OHdG 
measurement and a high throughput analysis capable in mass screening in nanotoxicological 
investigations. 
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Chapter 4. Integrate the electrochemical sensing platform to the LFS for biomarker detection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was submitted as follows (with slight modifications): X. Zhu, P. Shah, S. Stoff, 
H. Liu and C. Z. Li, "A paper electrode integrated lateral flow immunosensor for quantitative 
analysis of oxidative stress induced DNA damage", Analyst, 139 (11), 2850 - 2857, 2014. 
-Reproduced by permission of The Royal Society of Chemistry 
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4.1. Introduction 
LFS can provide a low-cost, easy-to-use and portable platform and have been widely used in 
many areas.35, 40, 42, 56, 62, 138 In LFS, the primary goal is to visualize colorimetrically the 
qualitative or semi-quantitative status of the analytes. Readout of the test results is performed 
optically, either by a machine such as a reflectometer or by the unaided human eye. In the 
previous chapter, we successfully designed and developed a LFS for semi-quantitative 8-
OHdG detection in both standard solution and cell model with the help of an image 
processing program “ImageJ”. However, LFS is known to be more prone to develop false 
positive (indicates that a person has a specific disease or condition when the person actually 
does not have it, which would increase the expense because of the reexamination) or false 
negative result (indicates a person does not have a disease or condition when the person 
actually does have it, which may miss the best treatment time) if applied to real samples, such 
as urine and blood, especially patient originated ones. The absorption of antibodies on the 
surface of AuNPs heavily relies on the hydrophobic and ionic interaction. A “bad” sample 
with either high ionic strength, high urea concentration or low pH139 accelerates the 
dissociation of the antibody-AuNPs complex, leading to false results. 
 
Electrochemical detection is an attractive method due to its capability of quantitative analysis, 
eases to be miniaturized to be portable, and produces less background. Therefore, in our 
specific aim 2, we tried to integrate an electrochemical sensing system to the LFS to develop 
a device which combining the electrochemical detection method with the previous 
colorimetrical detection method. Many studies have focused on applying electrochemical 
detection to the traditional POCT analytical devices in order to compensate for the limitations 
of colorimetric detection. Yang et al.140 pioneered the use of paper based electrodes 
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fabricated by sputtering silver directly onto a paper substrate through the development of a 
disposable Clark-type oxygen sensor. Dungchai et al.26 demonstrated a paper screen-printed 
electrode based device for electrochemically quantitative analysis of glucose, lactate and uric 
acid. Nie et al.28 followed a similar approach using paper based electrodes to detect heavy 
metal ions and glucose. These results reveal that the combination of electrochemical 
detection on paper based devices is a promising route to generate robust and cost efficient 
quantitative analytical tools.  
 
Most of these researches are based on a fact that the analyte itself can be electrochemically 
detectable. The DNA oxidative damage biomarker we used in the specific aim 1, 8-OHdG, 
has redox properties and can be detected by electrochemical method when it undergoing 
oxidation via a two-electron two-proton charge transfer reaction (Figure 4.1141), which has 
been well characterized for quantitative measurement.142 Thus, we used 8-OHdG as a 
representative in this section to evaluate the new developed platform. 
 
 
Figure 4.1. Schematic showing electroactive behavior of 8-OHdG. 
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8-OHdG displays a defined oxidation peak at a potential of 0.42 V (vs. Ag/AgCl reference 
electrode), which can be detected by Chronoamperometry technique. Chronoamperometry 
offers a better signal-to-noise ratio than other electrochemical techniques in this type of 
applications, and the use of a thin slab of fluids mechanically clamped to the electrodes is 
more resistant to vibration than analysis in a larger volume of solution.143 The 
chronoamperometric measurement of current—reflecting charge transfer to/from the redox-
active species as a function of time at constant applied voltages—begins with an initially 
large capacitive current. Upon the decay of the initial capacitive current within 1–2 s, 
Faradaic current (the current that is proportional to the concentration of the analyte) 
dominates. The current, i, decays as t-1/2 as described by the Cottrell equation.143 (eqn (1)) 
݅ = nFAD
ଵ/ଶC
πଵ/ଶtଵ/ଶ 																		(1) 
where n is the number of electrons, t is the time, F is Faraday’s constant, A is the area of the 
electrode, D is the diffusion coefficient of analytes, and C is the initial concentration of the 
reactants. The designed paper-based electrochemical device confines fluids in the paper 
channel, inhibits the convective movement of fluids, and thus facilitates the 
chronoamperometric measurements by minimizing the disturbances of the stationary 
boundary layer in the vicinity of electrodes due to vibration, thermal or density-based 
convection, and other disturbing sources.28  
 
As we mentioned previously, 8-OHdG is one of the predominant forms of free radical-
induced lesions of DNA. Because oxidative DNA lesions, i.e., oxidized nucleosides and 
bases, are reasonably water soluble and excreted into the urine without being further 
metabolized, urinary 8-OHdG is considered an important biomarker of generalized and 
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cellular oxidative stress.144 In fact, urinary 8-OHdG levels have been most frequently 
measured to indicate the extent of oxidative damage, since it is a non-invasive and 
technically less involved procedure.145 The major concern with the measurement of 8-OHdG 
by electrochemical method is the potential interference of 8-OHdG containing short 
nucleotides. As the products of 8-OHdG are repaired, both 8-OHdG molecule and 8-OHdG 
containing short nucleotides are present in biological urine samples145, with 8-OHdG being 
the major form usually. Existence of 8-OHdG containing short nucleotides will significantly 
quench the signaling in electrochemical assay set up for 8-OHdG molecule. The occurrence 
and proportion of 8-OHdG containing short nucleotide is relatively similar in normal 
biological samples, but might vary appreciably across healthy individuals and patients.  
 
To overcome the drawbacks of strip assay and electrochemical method for 8-OHdG detection, 
we designed and report here a novel sensing system by  integrating carbon nanotubes (CNTs) 
paper electrodes and immunochromatographic strip (referred to as an electrochemical 
immunosensor, ECIS) for quantitative analysis of 8-OHdG in both standard solution and 
urine samples. The sensing device combined competitive AuNPs based immunoassay of 
lateral-flow format with miniaturized paper electrodes for both colorimetrical and 
electrochemical detection. On the one hand, electrochemistry does not rely on the 
conjugation of AuNPs and antibodies, and thus could functions normally when the 
colorimetric method gives false positive results due to dissociation of AuNPs from antibody. 
On the other hand, immunostrip assay is able to respond to both the 8-OHdG molecule and 
the 8-OHdG containing short nucleotides and thus functions normally for biological samples 
containing high 8-OHdG containing short nucleotides. The optimized system was capable of 
achieving a detection limit of 2.07 ng mL-1 for 8-OHdG while only requiring 10 min to 
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complete the assay, which is comparable with the commercialized ELISA kit (detection limit 
is around 0.5 ng mL-1). The normal range of urinary 8-OHdG is given differently by using 
different methods (10-20 ng mL-1 by sophisticated methods (i.e. HPLC-ECD, GC-MS and 
CE-ECD)146-149 and 20~60 ng mL-1 by ELISA method81, 150-152). Based on these data, we can 
conclude that this novel device can provide a simple and fast tool for quantitative assessment 
of DNA oxidative stress in urine samples. Furthermore, the integrated platform can be further 
upgraded and optimized into a wireless-enabled biosensing system in future.  
 
4.2. Experimental 
4.2.1. Materials and equipment 
Nitrocellulose membrane, glass fibers, absorbent materials and polyester backing materials 
(Millipore (Billerica, MA)). Buckeye CNT paper (Buckeye Composites NanoTechLabs, Inc. 
(Kettering, OH)). Silver/Silver Chloride conductive ink (Conductive Compounds, Inc. 
(Hudson, NH)). Mouse monoclonal antibodies to 8-hydroxyguanosine and polyclonal Goat 
anti Mouse IgG (Abcam (Cambridge, MA)). 8-hydroxy Guanosine and 8-hydroxy-2-deoxy 
Guanosine (Cayman chemical (Ann Arbor, MI)). Gold chloride trihydrate (HAuCl4 •3H2O), 
Sodium periodate (NaIO4), Sodium phosphate (Na3PO4), Sodium chloride (NaCl), Sodium 
borohydride (NaBH4), Potassium carbonate (K2CO3), Ethylene Glycol and Bovine serum 
albumin (powder) (Sigma-Aldrich (St. Louis, MO)). Silver conductive adhesive paste, Tri-
Sodium Citrate Dihydrate, Triton X-100 and Phosphate buffered saline (PBS, 1X, PH=7.4) 
(VWR (West Chester, PA)). Tris–HCl (1 M), Tween® 20 (polyoxyethylene-20-sorbitan 
monolaurate) and Sucrose (Fisher Scientific (Fairlawn, NJ)). Zetasizer was from Malvern 
Instruments, (Woodstock, GA). Laminator (Office Depot). HP Scanjet G3110 Photo Scanner 
(Hewlett-Packard (Palo Alto, CA)). Dispenser Linomat 5 (CAMAG (Wilmington, NC)). 
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Drying Oven (VWR (West Chester, PA)). Cyclic voltammetric (CV) and 
Chronoamperometric measurements were performed with an electrochemical analyzer CHI 
660C (CH Instruments, Austin, TX).  
 
4.2.2. Preparation of the immunochromatographic strip 
The LFS specific for 8-OHdG detection were prepared following similar method outlined in 
section 2.2 with slight modification. The strip consists of four components: sample loading 
pad, conjugated pad, nitrocellulose membrane, and absorption pad, all of which were pasted 
onto a plastic backing plate. AuNPs with average diameter 20 nm were synthesized by citrate 
reduction method (section 2.2.1). Ab-AuNPs conjugates and BSA-8 hydroxyguanosine 
conjugates were prepared according to the reported protocol in section 2.2.2 and 2.2.4.1. A 
desired volume (25 μL) of Ab-AuNPs mixture was dispensed by pipette onto a glass fiber 
pad (6 mm × 5 mm), which was dried at room temperature and stored in desiccators at 4 °C 
before use. The sample loading pad (6 mm × 16 mm) was made from glass fiber and soaked 
with a buffer containing 0.15 mM NaCl, 0.05 M Tris-HCl and 0.25% Triton X-100. The pad 
was dried in an oven for 20 min at 50 °C and stored in desiccators at room temperature. BSA-
8 hydroxyguanosine conjugates were used as the test line (T) capture reagent, while goat 
anti-mouse IgG (1 mg mL-1) was used as the control line (C) capture reagent. These capture 
reagents were dispensed by the Linomat 5 dispenser at different locations on a nitrocellulose 
membrane (30mm × 10 cm) as the  test and control lines (separation distance is 13 mm). 
The membrane was mounted onto the adhesive backing plate in advance. The prepared plate 
(with nitrocellulose membrane and absorption pad) was cut into 6 mm-wide strips using a 
strip cutter and stored at 4 °C until use. Finally, all of other parts were assembled on the 
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adhesive backing layer. Each part overlapped 2 mm to ensure solution migration through the 
strip during the assay. 
 
4.2.3. Fabrication of CNTs conductive paper integrated immunostrip (ECIS) 
The structure of ECIS (Figure 4.2a) is similar to that of the traditional LFS. Besides the four 
required components, two electrodes were integrated into the original strip to carry out the 
electrochemical detection function. Briefly, CNTs conductive paper (2 mm in width) bought 
from Buckeye Composites was used as the working electrode. The CNTs paper was placed 
on the control line with the sensing surface facing down, and its extension beyond the strip 
was laminated with a silver plated copper wire to be connected to an electrochemical 
analyzer. Ag/AgCl ink painted copper paper (4 mm in width) was placed at a 1 mm distance 
from the CNTs paper on the side farthest from the absorption pad to serve as the 
reference/counter electrode. Finally, the entire strip was laminated (Fig. 4.2b) in order to 
ensure complete contact between the sample, membrane and electrodes. 
 
 
Figure 4.2 (a) A schematic for ECIS; (b) Photograph of a representative ECIS. 
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4.2.4. Preparation of standard and spiked urine samples 
General procedures found in section 2.3.3. 
 
4.2.5. Coupled chronoamperometric and colorimetric measurements of 8-OHdG 
Chronoamperometric measurements were performed with an electrochemical analyzer CHI 
660C or a portable electrochemical analyzer connected to a personal computer. A fully-
integrated ECIS sensor was connected to the analyzer in advance and conductivity of the loop 
was examined. 100 μL of standard solution or of urine sample solution containing the desired 
concentration of 8-OHdG was applied to the sample application zone. After waiting for a 
specified time period (10 min), chronoamperimeric measurements (fixed potential: 0.42 V, 
sample duration: 20s) were performed by using the software. At the same time, a photograph 
of the strip was then taken using a digital scanner. The software ImageJ was used to quantify 
the intensity of test lines for colorimetric analysis. 
 
4.2.6. Quantitative analysis 
Current readout from chronoamperimeric measurements and color intensity from 
colorimetric tests are expressed as the mean ± SD of six experiments. The data were analyzed 
quantitatively either by using ImageJ and/or Excel software. 
 
4.3. Results and discussion 
4.3.1. Material selection for electrochemical sensing system-CNTs Paper 
Suitable materials of electrode need to be selected for the electrochemical sensing system. 
We fabricated several screen-printed electrodes by using different electrode materials and 
different substrates, such as silver-based electrodes and gold thin-film electrodes. We also 
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tried various commercialized screen-printed electrodes which are constructed by more 
advanced nanomaterials including graphene electrodes, gold nanoparticle decorated 
electrodes and CNTs electrodes. These electrodes have their own advantages and 
disadvantages in terms of sensitivity, simplicity and cost-effectiveness. However, based on 
their performances on 8-OHdG detection and the design of the sensor, a flexible electrode 
which can be easily integrated into the strip and of high electrochemical activity is preferred. 
CNTs conductive paper, bought from NanoTechLabs, Inc., was finally selected as the 
electrochemical sensing component as it is flexible as well as has high electrochemical 
activity. Before using the CNTs conductive paper to create the test strip, we characterized the 
CNTs paper by using scanning electron microscope (SEM). The surface structure of CNTs 
conductive paper is shown in Figure 4.3. Instead of the sheet or net structure most often 
found in CNTs, the figure shows a forest structure which can provide a larger surface area 
and better sensitivity, both qualities which are suitable for our applications. 
 
 
Figure 4.3 SEM characterization of CNTs paper 
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4.3.2. Principle of the ECIS for 8-OHdG detection 
The method of the biosensor is based on two principles: the first principle is that of 
competitive-type immunoreactions in the LFS as demonstrated in the previous chapter; the 
second principle is the ability of 8-OHdG to be electrochemically detected when undergoing 
oxidation via a two-electron two-proton charge transfer reaction (Figure 4.1)  
 
In a typical assay, a sample solution containing a desired concentration of 8-OHdG is applied 
to the sample application pad (Figure 4.4 (A)). The sample moves along the strip due to 
capillary force and rehydrates the AuNP-anti-8-OHdG in the conjugation pad. Then the 
immunoreactions between 8-OHdG and AuNP-anti-8-OHdG conjugates occur and the 
formed AuNP-anti-8-OHdG-8-OHdG complexes continue to migrate along the strip (Figure 
4.4 (B)). When they reach the test zone, the unbound AuNP-anti-8-OHdG conjugates are 
captured by the BSA-8-hydroxyguanosine conjugates immobilized on the test zone via the 
same immunoreactions. The accumulation of AuNPs on the test zone induces a characteristic 
red band which is visible with the naked eye (Figure 4.4 (C)). This color change 
accomplishes the colorimetric detection of 8-OHdG in a sample and the color intensity is 
inversely proportional to the concentration. The capillary action causes the liquid sample to 
migrate further. Once the solution passes through the control zone, the AuNP-anti-8-OHdG 
Ab-8-OHdG complexes and excess AuNP-anti-8-OHdG conjugates are captured on the 
control zone by the pre-immobilized polyclonal Goat anti-Mouse IgG, thus forming a second 
red band showing that the biosensor is operating properly (Figure 4.4 (D)). 
Chronoamperometric measurement of the control line was performed (exactly 10 min after 
applying the sample) using electrochemical analyzer providing the data to produce the 
Current vs. Time curves (Figure 4.4 (E)). Qualitative analysis of the colorimetric test is 
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simply performed by observing the color change of the test zone, and quantitative analysis is 
realized by reading the optical intensities of the red bands with a scanner (just after the 
chronoamperometric measurement). The peak area (Figure 4.4 (F)) is proportional to the 
amount of the captured Au-NPs in the test zone, which is inversely proportional to the 
concentration of 8-OHdG in the sample solution. 
 
 
Figure 4.4 Principle of the ECIS for 8-OHdG quantitative detection. 
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4.3.3. Electrochemical characterization of CNT conductive paper-based electrodes 
Before using ECIS devices for analytes measurement, the functionality of the electrodes was 
established. A potassium ferricyanide/ferrocyanide (K3Fe(CN)6/K4Fe(CN)6) mixture was 
used as a model redox-active compound to characterize electrochemical behavior of the 
CNTs conductive paper. 100 mM K3Fe(CN)6/K4Fe(CN)6 stock solution was prepared by 
dissolving these two chemicals in PBS (1X) buffer, corresponding working solutions can be 
obtained by altering the dilution. Figure 4.5 shows the cyclic voltammetric response for the 
compound in the two electrode system at various scan rates. The peak shape of CVs 
demonstrates a typical reversible electrochemical reaction, indicating that no side reactions 
take place and the kinetics of electron transfer is sufficiently rapid to maintain the surface 
concentrations of redox-active species at the values required by the Nernst equation. Next, 
the dependence of peak current on the square root of the scan rate was studied. The insert in 
Figure 4.5 shows that anodic and cathodic peak currents were directly proportional to the 
square root of the scan rate (v1/2) between 10 and 200 mV s-1. The linearity indicates that the 
mass transfer in this system is a diffusion controlled process similar to the behavior of 
traditional electrochemical cells. 
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Figure 4.5 Representative cyclic voltammograms of 5.0 mM K3Fe(CN)6/K4Fe(CN)6 solution 
(pH=7.0) in two electrodes system at various scan rates: 10, 25, 50, 100, and 200 mV s-1. We 
used a 2 mm by 6 mm CNT conductive paper electrode as the working electrode, and a 
printed Ag/AgCl electrode as the reference/counter electrode. The relationship between 
anodic and cathodic currents and the square root of the scan rate is shown in the insert. The 
red lines represent the linear regression line between ip,ox or ip,re and (ν)1/2, respectively. 
 
4.3.4. Colorimetric measurement of analytes in buffer by ECIS 
A series of 8-OHdG standard solutions with concentrations of 0, 1, 10, 20, 50, 80, 100, 150, 
200, and 1000 ng mL-1 in 1X PBS buffer were prepared and applied to the sample pad. After 
10 min, chronoamperometry at the electrodes and color intensity of the test lines were 
recorded according to the method in the methodology section 4.2.5. The color bar (Figure 
4.6a) shows the typical responses on test lines of the strips to 8-OHdG with increasing 
concentrations from 0 to 1000 ng mL-1. The color intensity deceased when the sample 
concentration increased which is consistent with the theory of competitive format detection. 
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The color bar can easily be used as a reference, each color representative of the results for 
equivalent concentration of the analyte. 
 
Figure 4.6b demonstrates the calibration curve produced by introducing samples of varying 
concentrations of 8-OHdG into the strips, revealing a logarithmic relationship between the 
color intensity and the concentration. Normalized intensity defined by average sample 
density (ASD) / average blank density (ABD) of the test line is used as the y-axis. As these 
are intended to be single-use test strips, each data point represents the average response from 
three separate test strips. The error bars represent the standard deviation. Most 
commercialized ELISA kit can detect urinary 8-OHdG concentration in the range of 0.64 to 
200 ng mL-1 (i.e. KOG-200SE, Genox). This range was used as a reference for linearity study. 
The insert for Figure 4.6b shows that a linear response is observed for the concentrations 
between 1 ng mL-1 and 200 ng mL-1 (logarithm scale) where the coefficient of determination 
(R2) is greater than 0.99. The limit of detection (LOD), calculated based on three times the 
standard deviation of blank, was found to be 2.07 ng mL-1. The result shows that this strip 
can potentially be used as a simple, rapid and low cost platform with acceptable detection 
limit and range for 8-OHdG measurement compared with other traditional methods. 
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Figure 4.6 (a) Color bar represents 8-OHdG standard solutions with varying concentrations. 
(b) Dose-response curve for 8-OHdG based on optical density analysis using standard 
samples. Values are mean ± SD from three independent experiments. The normalized 
intensity of the test line is plotted against the concentration of 8-OHdG in the logarithm scale 
as shown in the insert. (c) Dose-response curve for 8-OHdG based on optical density analysis 
using urine samples. Values are mean ± SD from three independent experiments. The 
normalized intensity of the test line is plotted against the concentration of 8-OHdG in the 
logarithm scale as shown in the insert (solid line, 1-200 ng mL-1; dash line, 10-200 ng mL-1). 
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4.3.5. Colorimetric measurement of analytes in urine samples by ECIS 
After confirming the feasibility of this device for standard 8-OHdG solutions measurement, it 
was evaluated as a tool for urine sample testing. A series of 8-OHdG spiked urine samples 
with the same concentrations of those in PBS buffer were prepared and applied to the strips. 
 
Figure 4.6c shows the normalized intensity curve rendered from the urine samples spiked 
with varying 8-OHdG concentrations. As expected, the changing trend of the curve is similar 
to that of the standard solutions. We also drew two linear fitting curves for the urine samples 
over the whole and partial concentration range (solid line, 1-200 ng mL-1; dash line, 10-200 
ng mL-1), shown in the insert. A linear response is also observed for concentrations between 1 
ng mL-1 and 200 ng mL-1 (logarithm scale) where the coefficient of determination (R2) is 
greater than 0.95. The LOD, calculated as previously, was found to be 5.76 ng mL-1, which is 
still sensitive enough for 8-OHdG measurement in urine samples from both healthy and non-
healthy patients (As mentioned previously, healthy human subjects have urinary 8-OHdG 
levels in the range of 10 to 60 ng mL-1. While the levels go up 2~4 times higher for the non-
healthy patients depend on different types of diseases).146-148, 150, 153-155 
 
The slope obtained from the whole range fitting (solid line) is significantly bigger than that 
generated from spiked PBS samples, which maybe is the result of 8-OHdG originally present 
in the urine samples (2-8 ng mL-1 after 1/10 dilution), resulting in a considerable 
concentration shift for the left end data. For this reason the dash line produces a more 
accurate fitting with R2 as high as 0.9934 and slope of -0.2641 which is much closer to that of 
spiked PBS sample. 
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Nevertheless, in reality there are various types of bio-molecules in urine which may affect the 
antigen-antibody interaction and stability of antibody-AuNP complex, leading to lower 
discrimination among different 8-OHdG concentrations. This presents one possible 
explanation for the bigger slope in spiked urine samples even after the deletion of first data 
point when compared to that of PBS. It is worth noting that, this is a universal problem for 
immunoassays, biological samples from different individuals may interfere with immuno-
reactions differently. There are some easy methods that could be used, such as 1/10 dilution 
for personal testing and molecular size based filtration or centrifugation in laboratory, to 
minimize these difference in interference. A complete establishment of a marketed 
immunoassay for a particular molecule still requires the evaluation of different interference 
of samples from individuals across healthy individuals and patients, which is one of our 
follow-ups in future works. 
 
4.3.6. Chronoamperometric analysis of 8-OHdG in the ECIS 
At the start of our study, we employed numerous electrochemical techniques including cyclic 
voltammetry, square wave voltammetry, etc. for 8-OHdG measurement in the ECIS system. 
For most techniques, 8-OHdG can only be detected in high concentrations, making such 
techniques unsuitable for use in clinical research. Chronoamperometry, which offers a better 
signal-to-noise ratio than other electrochemical techniques, is able to detect 8-OHdG in lower 
concentrations. Thus, this method was used as the standard detection approach for the 
following study. 
 
Prior to chronoamperometric measurement, cyclic voltammetry was used to determine the 
oxidation potential of 8-OHdG (0.42 V) in the ECIS system with high concentration. 
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Subsequently, chronoamperometric measurements were performed at a fixed step potential 
(0.42 V) after applying the 8-OHdG samples (standard or urine) to the strips for 10 min (prior 
to taking photographs for colorimetric tests). Figure 4.7a shows a representative 
chronoamperometric response to the measurements of 8-OHdG using ECIS. Over the range 
of concentrations of 8-OHdG examined (0–150 ng mL-1), all the response curves reached a 
steady state 2 s after the step potential. Figure 4.7b shows the corresponding calibration 
curves for the detection of 8-OHdG in both standard and urine solutions (n = 6). When the 
concentration of 8-OHdG is in the range of 0-150 ng mL-1, the current is linearly proportional 
to the 8-OHdG concentration with the correlation coefficient of R2 = 0.99 in standard 
solutions and that of R2 = 0.97 in urine samples. From the calibration plot, comparable 
detection limits (compared to the colorimetric method) of 3.11 ng mL-1 in standard solutions 
and 8.85 ng mL-1 in urine samples were calculated, which are still sensitive enough for 8-
OHdG measurement in human urine samples. 
 
Both the higher detection limitation and bigger slope in spiked urine samples indicate that 
background of urine lower the sensitivity of electrochemical detection of 8-OHdG.  One 
reason for this is because the background urine has a completely different ionic environment 
compared with buffer where electrochemistry will occur quantitatively differently. Another is 
because 8-OHdG present in the urine samples resulting in a considerable concentration shift 
for the left end data. As discussed previously, there are some easy methods that could be used 
to minimize these difference in interference, such as 1/10 dilution of the background urine or 
using an artificial urine for calibration.  
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Figure 4.7 (a) Representative chronoamperometric curves for 8-OHdG concentrations (ng 
mL-1): 0, 20, 50, 80, 100 and 150 in the ECIS; (b) Calibration plots of current as a function of 
the 8-OHdG concentration for its detection in standard solutions (black circle) and in urine 
samples (black triangle). We used CNTs conductive paper as the working electrode and 
silver/silver chloride as the counter/reference electrode, respectively. The working electrode 
had a surface area of 12 mm2 in contact with the solution in both standard and urine. The 
distance between electrodes was 1.0 mm. A 420 mV step potential was used to generate the 
calibration curve. The solid lines represent a linear fit to standard with regression equation: y 
= -1.2215 – 0.0895x (R2 = 0.9947, n=6). The dash line represents a linear fit to urine samples 
with the regression equation: y = -1.3803-0.0564x (R2 = 0.9691, n=6). 
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In a strict sense, our device is not a complete POCT device at this research stage because of 
sample preparation (dilution) and electrochemical analyzer employment.  However, these can 
be avoid by using artificial urine as the background urine for calibration and applying a 
portable analyzer which is compacted and can be connected to a wireless electronic device 
for reading in the near future. Therefore, we provide a protype here for concept 
demonstration, and optimizations are still needed for complete POCT and commercialization. 
 
4.4. Conclusions 
We demonstrate, for the first time, the coupling of CNTs conductive paper based 
electrochemical detection and traditional LFS based colorimetric detection to provide rapid 
(~10 min) quantitative measurement of DNA oxidative damage biomarkers (8-OHdG) in 
both PBS and spiked urine samples, exhibiting the feasibility of using this device in medical 
diagnosis. The two methods on one single strip are both able to quantitatively detect levels of 
8-OHdG concentrations, with detection limitation of 2.07 ng mL-1 for colorimetric method 
and 3.11 ng mL-1 for electrochemical method that are low enough for patient testing in the 
field. Integration of these two detections provides a platform where cross check of 8-OHdG 
measurement could be achieved. Using this system, testers could get higher confidence on 
double positive or double negative results. In addition, this system minimizes the chance of 
false negative or false positive by compensation between these two methods differing in 
principle. Future efforts will be made to optimize our system to be suitable to be connected to 
a wireless-enabled electronic system for portable and quantitative assessment of oxidative 
stress induced DNA damage.  
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Chapter 5. Integrate a personal glucose meter with the traditional LFS for portable and 
quantitative detection of biomarkers 
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5.1. Introduction 
We successfully coupled the electrochemical sensing platform to the LFS in the previous 
chapter. This sensing strategy, which is called ECIS, provides a simple and low cost platform 
for quantitative biomarker detection with high sensitive and accuracy. As mentioned 
previously, an important superiority for this platform is that it can be potentially connected to 
a portable electronic device for quantitative and instant measurements, which is a key 
perspective for the future POCT development. At the same time, electrochemical detection 
usually based on a fact that the analyte itself should be electrochemically detectable. 
Therefore, in this chapter, we tried to test an electrochemical integrated LFS platform by 
connecting to a portable device. This portable device can detect any analytes with or without 
electrochemical properties by electrochemical method. PGM is the most popular and 
accessible portable electronic device on the market and used here to demonstrate the concept 
of our design. A small molecule, 8-OHdG and a large protein molecule, prostate-specific 
antigen (PSA) are used as the representative non-glucose targets to test the feasibility of the 
device. 
 
Prostate cancer (PCa) has become one of the most frequently diagnosed cancers and the third 
leading cause of cancer morbidity and mortality among males in the United States.156 
Therefore, early and sensitive diagnosis of PCa is needed to initiate therapy to avoid the 
progression of the disease. It has been shown that serum PSA is the most reliable tumor 
marker to detect PCa at the early stage and to monitor recurrence of the disease after 
treatment.157-160 Currently, most PSA testings take place at dedicated centralized laboratories 
using large, automated analyzers, requiring sample transportation, increased waiting time and 
increased administration and medical costs.161, 162 Near-patient or POCT is highly needed to 
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reduce the number of clinic visits, decrease costs to the patient and the healthcare system, 
increase patient satisfaction and improve clinical outcome. Recent advances in biosensor 
development based on nanomaterials and nanostructures as integral components have brought 
POCT for PSA closer to reality.  
 
In recent years, much effort has been devoted toward developing POCT devices.13, 24, 163-169 
Among them, paper-based POCT devices is a special category due to the advantages of being 
simple, rapid, on-site, and cost-effective; they have been widely used in home healthcare and 
medical testing,56, 61, 138 even environmental monitoring.39, 40, 170 LFS is one of the simplest 
and most popular formats of paper-based POCT devices, and can be used to detect specific 
substances including small molecules,40, 60, 171, 172 large proteins15, 58, 173 and even whole 
pathogens,138 in a sample by using an immunological reaction. However, most of these tests 
are based on qualitative colorimetry, which is not sufficient in many cases. To overcome this 
limitation, a number of devices capable of quantitative analysis have been developed. 
 
As we know, medical devices for POCT are very costly to develop and manufacture, and are 
difficult to commercialize. As a result, few have been successfully commercialized. The 
PGM is one of the most successfully commercialized diagnostic devices on the market,174, 175 
and it has been widely used by millions of diabetes patients to monitor their blood glucose 
levels every day because of its low cost, compact size, simple operation and reliable 
quantitative results.163 The recent successful launch of FDA-approved smartphone-enabled 
PGMs which enable the wireless transmission of reminders, test results, and data analysis 
through smartphone apps will attract even larger number of users.176  
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Most glucometers today use an electrochemical method (Figure 5.1). Test strips contain a 
capillary that sucks up a reproducible amount of blood. The glucose in the blood reacts with 
an enzyme electrode containing glucose oxidase (or dehydrogenase). The enzyme is 
reoxidized with an excess of a mediator reagent, such as a ferricyanide ion (a ferrocene 
derivative or osmium bipyridyl complex). The mediator in turn is deoxidized by reaction at 
the electrode, which generates an electrical current. The total charge passing through the 
electrode is proportional to the amount of glucose in the blood that has reacted with the 
enzyme. From this detection mechanism, we can conclude that the glucose meter is capable 
of detecting glucose as the unique target. 
 
 
Figure 5.1 Detection mechanism of glucose meter. Image taken from Bioanalytical Systems 
Inc. 
 
In order to realize non-glucose target detection by using a PGM, the relationship between 
target recognition and glucose generation must be established. Recently, many groups have 
reported methods establishing a direct relationship between the concentrations of the targets 
in the samples and the glucose detected by a PGM, enabling a number of non-glucose targets 
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to be detected quantitatively.163, 177, 178 However, most of these methods included much liquid 
handling, such as adding and mixing solution, which should be avoided as much as possible 
to ensure ease of use. Conversely, a lateral flow device, as mentioned previously, is supposed 
to replace most of the manual solution addition and mixing involved in the above methods. 
 
The basic design of the device is adapted from the previous colorimetric detection platform 
based on AuNPs based immunoreactions (in specific aim 1 and 2). However, visual detection 
can provide only qualitative and semi-quantitative results. Thus, to enable quantitative 
analysis, we establish a novel method that correlates the detection of non-glucose target to 
the detection of an enzyme-invertase by the target-induced immunoreactions. Subsequently, 
the enzyme converts sucrose into glucose for PGM readout. 
 
5.2. Experimental 
5.2.1. Materials 
Bovine serum albumin, Invertase from baker’s yeast, Sucrose, Gold chloride trihydrate, 
Sodium borohydride, Sodium periodate, Ethylene Glycol, Potassium carbonate, Boric acid, 
Sodium chloride and Prostate Specific Antigen from human semen (Sigma-Aldrich (St. Louis, 
MO)). NeutrAvidin Agarose, Streptavidin, EZ-Link Hydrazide-Biotin and Biotin 
Quantitation Kit (Pierce Biotechnology (Rockford, IL, USA)). Trehalose, PBS (1X, pH=7.4) 
and Tri-Sodium Citrate Dihydrate (VWR (West Chester, PA)). Tween 20 (Fisher Scientific 
(Fairlawn, NJ)). Plastic backing, Nitrocellulose membrane, Absorbing pad and cellulose 
paper (Millipore (Billerica, MA)). Streptavidin Conjugated Gold Nanoparticles (Nanocs Inc. 
(New York, NY)). 8-hydroxy-2-deoxy Guanosine and 8-hydroxy Guanosine (Cayman 
chemical (Ann Arbor, MI)). Mouse monoclonal antibodies to 8 hydroxyguanosine (biotin), 
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Mouse monoclonal [PS2] to prostate specific antigen (Biotin), Mouse monoclonal [PS6] to 
Prostate Specific Antigen and polyclonal Goat anti Mouse IgG (Abcam (Cambridge, MA)). 
PGM (TRUEtrack) and test strips (Walgreens (Springfield, IL)). 
 
5.2.2. Preparation of streptavidin coated gold nanoparticles (STV-AuNPs) 
The AuNPs were synthesized by the same protocol as described in section 2.2.1. For 
Streptavidin labeling, the AuNPs solutions was concentrated 5-fold (5X) in advance and the 
pH was adjusted to 6.8~7.2 with K2CO3 (0.1 M). Before conjugation, the optimal 
concentration of protein was determinated by the same protocol in section 2.2.2. Simply, 
streptavidin solutions (20 μL) with different concentrations (0, 0.1, 0.25, 0.5 and 1 mg mL-1) 
were mixed with gold solution (5X, 100 μL, pH 6.8-~7.2) and incubated for 15 min at room 
temperature, and then 10% NaCl solution was added. The color of samples changes from 
brilliant red to blue as the concentration of Streptavidin decreases. The optimum 
concentration for labeling was the lowest concentration of mAb that did not change color, 
which is 0.25 mg mL-1. 
 
At the same time, we also measured the zeta potentials of the five mixtures (after 1 h 
incubation and two times purification). We found that the zeta potential (Table 5.1) became 
less negative when the concentration of streptavidin increased, but there was no obvious 
change when the concentration is larger than 0.5 mg mL-1. Based on the previous two 
experiments, 0.5 mg mL-1 was chosen as the optimal concentration for labeling. 
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Table 5.1 Zeta potential of five mixtures 
Sample (20 μL, mg mL-1) Zeta potential (mV) SD (n = 3) 
0 -52.7 ±2.21 
0.1 -26.87 ±0.29 
0.25 -20 ±0.82 
0.5 -7.78 ±0.43 
1 -7.18 ±0.44 
 
5.2.3. Preparation of biotin-invertase 
Biotin was conjugated to sialic acid residues of invertase by using a EZ-Link Hydrazide-
Biotin kit. The efficiency of biotinylation was tested through NeutroAvidin Agarose. Briefly, 
an aliquot (30 μL) of agarose beads were separated and resuspended in 200 μL PBS buffer 
containing biotin-invertase (0.25 mg mL-1), and the mixture was incubated for 1 h. Then the 
mixture was centrifuged for 2 min and the supernatant was collected. 10 μL of the 
supernatant and biotin-invertase solution (0.25 mg mL-1) were mixed with 50 μL 0.5 M 
sucrose solution respectively. After 30 min, the readout of PGM (TRUEtrack Walgreen) was 
collected. From the result (Table 5.2), we can conclude that the efficiency of the biotinylation 
of the enzyme was greater than 70%. 
 
Table 5.2 Efficiency of the biotinylation of the enzyme 
PGM readout  
(mg dL-1) 
Biotin-invertase 
(10 μL, 0.25 mg mL-1)
Supernatant 
(10 μL, 0.25 mg mL-1) 
30 min 61 (n =3) Low (<20) (n =3) 
 
5.2.4. Preparation and characterization of invertase/Antibody-AuNPs 
An aliquot (100 μL) of the streptavidin coated gold nanoparticles (STV-AuNPs) was 
centrifuged and resuspended with 100 μL PBS buffer containing biotin-invertase (2.5 mg mL-
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1) and biotin-Ab (32.5 μg mL-1) for 1 h. Then the invertase/Ab-AuNPs conjugates were 
separated, washed with 1 % BSA/PBS and finally resuspended in buffer (50 μL) for further 
use. 
 
5.2.5. Preparation of BSA-8 Hydroxyguanosine conjugates 
Details found in section 2.2.4.1 
 
5.2.6. Assembly of the LFS 
Details are simlar to the section 2.2.5 with slight modification: The sample pad was 
pretreated with buffer (50 mM borate buffer, 1% BSA and 0.2% Tween-20), and 
invertase/Ab-AuNPs conjugates (20 uL) was dispensed by pipette onto a conjugate pad. 
 
5.3. Results and discussion 
5.3.1. Design and detection mechanism of the strip for non-glucose target detection by a 
PGM 
As shown in Figure 5.2, the test strip is composed of four components which were preloaded 
with different reagents and pasted onto a plastic backing plate. The sample pad pretreated 
with buffer (50 mM borate buffer, 1% BSA and 0.2% Tween-20) is where the strip contacts 
the liquid sample. Conjugation pad, which is composed of glass-fiber material, contains 
invertase/antibody (Ab)-conjugated AuNPs. Next to the conjugation pad is a flow membrane, 
which is made of nitrocellulose. There are two reaction zones on membrane, which are called 
test line and control line. BSA/8 hydroxyguanosine conjugates (1 mg mL-1) or Mouse anti-
PSA [PS6] antibody (1 mg mL-1) was used as the test line capture reagent, while Goat anti-
Mouse IgG Ab (1 mg mL-1)  was used as the control line capture reagent. These capture 
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reagents were dispensed by the Linomat 5 dispenser onto the nitrocellulose membrane. 
Sample moves along the strip due to capillary action and finally gets collected by the last part 
known as the absorption pad.  
 
 
Figure 5.2 Design of test strip for quantitative detection of 8-OhdG or PSA 
 
To realize non-glucose target detection using a PGM, the relationship between target 
recognition and glucose generation must be established. In our design, as illustrated in Figure 
5.3 and Figure 5.4, the detection is based on two steps: the first step is that of competitive-
type (for 8-OHdG, Figure 5.3 (A)(B)(C)(D)) or sandwich-type (for PSA, Figure 5.4 
(A)(B)(C)(D)) immunoreactions in the LFS; the second step (Figure 5.3 (E)(F)(G) or Figure 
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5.4 (E)(F)(G)) contains an enzymatic reaction which converts sucrose into detectable glucose 
for measurement by a PGM. 
 
Upon target introduction (Figure 5.3 (A) and 5.4 (A)), the target moves along the strip due to 
capillary force and rehydrate the conjugation pad, where the immunoreactions take place 
(Figure 5.3 (B) and 5.4 (B)). Subsequently, the invertase/Ab-AuNPs can be captured 
separately by the corresponding reaction zone based on the format of the Ab (Ab with free 
antigen-binding site will be captured by the BSA/8 hydroxyguanosine conjugates on the test 
line (Figure 5.3 (C); Ab saturated with 8-OHdG will be captured by the Goat anti-Mouse IgG 
on the control line (Figure 5.3 (D); Ab bounded with PSA will be captured by anti-PSA Ab2 
on the test line (Figure 5.4 (C); the rest Ab will be fixed on the control line (Figure 5.4 (D)). 
Competitive-type immunoreactions make the target (sample) compete with the antigen (test 
line) for the antibody from conjugation pad. As a result, the color intensity of the test line as 
well as the amount of invertase captured on the test line are inversely proportional to the 
target concentration in the sample. Instead, the amount of invertase captured on the test line 
is proportional to concentration of PSA in the sandwich assay. Followed by the first step (<10 
min), the test (2 mm) and control (2 mm) lines are cut by scissors and placed on a 
hydrophobic plate (Figure 5.3 (E) and 5.4 (E)). Then, 20 μL 0.5 M sucrose solutions are 
added on top of each zone (Figure 5.3 (F) and 5.4 (F)). After a specific period of time, the 
enzyme invertase fixed on each zone catalyzes the hydrolysis of sucrose to produce a specific 
amount of glucose for quantitative readout by the PGM (Figure 5.3 (G) and 5.4 (G)). 
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Figure 5.3 Mechanism for 8-OHdG detection by a PGM 
 
94 
 
 
Figure 5.4 Mechanism for PSA detection by a PGM 
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5.3.2. Check the properties of Invertase/Antibody-AuNPs conjugates 
The bifunctional AuNPs conjugated with invertase and antibody is one of the most important 
components in our design. The enzymatic product of invertase (glucose) can be monitored by 
a PGM. And the invertase/Ab-AuNPs are used as signal amplification labels, which can 
trigger each antibody-antigen recognition event into the capture of massive invertase. As a 
result, target-induced competitive or sandwich immunoreactions can lead to the capture of 
numerous invertases and generate a measurable amount of glucose that falls in the dynamic 
range of the PGM (0.6-33.3 mM or 10-600 mg dL-1). Therefore, two aspects of the functions 
of the conjugates were examined before being used for the conjugation pad: enzymatic 
activity (invertase part) for glucose production and immunoreactivity (antibody part) for 
competitive or sandwich immunoreactions.  
 
Firstly, the enzymatic activity of the conjugates was tested by mixing 10 μL conjugates 
solution with 50 μL 0.5 M sucrose solutions. The readout of PGM was 436 mg dL-1 (n = 3) 
after 10 min, indicating that conjugates possess a high enzymatic activity. Secondly, the 
immunoreactivity of the conjugates was tested through colorimetrical based antibody-antigen 
immunoreactions. Take 8-OHdG as an example, which is based on the theory of the 
competitive format of detection. 20 μL of the conjugates was applied onto the conjugation 
pad, which was subsequently assembled into a strip. 100 μL of samples with different 
concentrations were applied to the sample pad. After 10 min, photographs were taken by 
using digital camera. Figure 5.5 shows the typical responses of the strips to 8-OHdG with 
seven concentrations (0, 1, 2, 5, 10, 20, 100 ng mL-1). The color intensity of the test line 
deceased when the sample concentration increased, which was consistent with the theory of 
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detection of competitive format and demonstrating the feasibility of the fuction of antibody in 
the conjugates for the following application.  
 
 
Figure 5.5 The photographs of test strips based on seven concentrations (0, 1, 2, 5, 10, 20, 
100 ng mL-1) of 8-OHdG. 8 hydroxyguanosine-BSA conjugates were used as the test line; 
Goat anti-Mouse IgG were used as the control line. 
 
5.3.3. Quantitative analysis of 8-OHdG by integrating the PGM with the LFS 
To demonstate the feasibility of our method for 8-OHdG detection, a series of 8-OHdG 
solutions with concentrations of 0, 0.1, 0.5, 1, 2, 5, 10, 20, 50, 100, 150 and 200 ng mL-1 in 
1X PBS buffer were prepared and applied to the strips. After 10 min, the test (2 mm) and 
control (2 mm) lines were cut by scissors and placed on a hydrophobic plate. 20 μL of 0.5 M 
sucrose solution was put on top of each zone, and the PGM was used for readout after 45 
min. As shown in Figure 5.6a, PGM readings (test line) decreased when the concentration 
increased, which is consist with the theory of the competitive format of detection. When the 
concentration is larger than 100 ng mL-1, there was no obvious change in the PGM readings. 
However, elevated concentrations of 8-OHdG from 0.1 to 100 ng mL-1 lead to obviously 
decreased PGM readings. A dynamic range of 0 to 100 ng mL-1 can be obtained, and as low 
as 0.23 ng mL-1 of 8-OHdG can be detected.  
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Figure 5.6 (a) Detection of 8-OHdG in buffer based on the PGM. The concentration of 8-
OHdG was varied from 0 to 200 ng mL-1. Error bars: SD, n = 6; (b) Conventional 
colorimetric ELISA for various concentrations of 8-OHdG. The absorbance spectra were 
recorded at 450 nm. Error bars: SD, n = 3. 
 
In order to evaluate the analytical performance of the proposed method for 8-OHdG 
detection, a conventional ELISA approach was also performed for comparison. In the ELISA 
detection format, Horse Reddish Peroxidase (HRP) was used as a label to generate analytical 
signals. After the formation of the 8-OHdG-Ab1-Ab2/HRP in the ELISA plate wells, the 
3,3’,5,5’-tetramethylbenzidine (TMB) substrate for HRP was added and the UV-vis 
adsorption at 450 nm was recorded after acidification with sulfuric acid. As displayed in 
Figure 5.6b, the standard ELISA method for 8-OHdG indicates a detection range from 0.5 to 
200 ng mL-1, and the detection limit is about 0.64 ng mL-1. We performed a comparison 
between our method and ELISA on the detection of 8-OHdG in buffer with known 
concentrations, which is shown in Table 5.3. From this table, we can see that the results 
obtained from our method are very close to those indicated in the first column. Table 5.4 
illustrates that our PGM-based method can provide a simple, rapid, on-site and cost effective 
platform with acceptable detection limit and range in comparison with ELISA. 
 
98 
 
Table 5.3 Comparison between PGM-based method and ELISA on 8-OHdG detection in 
buffer samples (n = 6) 
 
 
Table 5.4 PGM-based method vs. ELISA on 8-OHdG detection  
 
 
5.3.4. Evaluate the PGM-based strip for 8-OHdG detection in human urine samples by 
comparing it with a conventional colorimetric ELISA 
As mentioned previously, urinary 8-OHdG is considered to be an important biomarker of 
generalized and cellular oxidative stress. To evaluate the PGM-based strategy for the 
detection of 8-OHdG in real biomedical applications, urine samples from four individuals 
with varying 8-OHdG concentrations were tested. These samples were also assayed with a 
commercial 8-OHdG ELISA kit as reference. As shown in Table 5.5, the results obtained by 
the PGM-based method are in agreement with those obtained by the ELISA approach in the 
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investigated 8-OHdG concentration, which indicates the developed PGM-based method 
could be applied to clinical samples. 
 
Table 5.5 Comparison between PGM-based method and ELISA on detection of 8-OHdG in 
human urine samples (n = 6) 
 
 
5.3.5. Quantitative analysis of PSA by integrating the PGM with the LFS 
The platform was then used for PSA detection. A series of PSA solutions with concentrations 
of 1, 5, 10, 20, 50, 100 and 200 ng mL-1 in 1X PBS buffer were prepared and applied to the 
strips. After 10 min, the test lines (2 mm) were cut by scissors and placed on a hydrophobic 
plate. 20 μL of 0.5 M sucrose solution was put on top of each zone, and the PGM was used 
for readout after 30 min. As shown in Figure 5.7, PGM readings increased when the 
concentration increased, which is consist with the theory of the sandwich format of detection. 
A dynamic range of 0 to 100 ng mL-1 can be obtained, and as low as 1.26 ng mL-1 of PSA can 
be detected, by the definition of 3σb/slope (σb, standard deviation of the blank samples). The 
detection limits achieved by the method indicate the promise for the detection of PSA in 
potential diagnosis applications of prostate cancer since the cutoff level of normal blood PSA 
concentration is 4 ng mL-1.179-183 
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Figure 5.7. Detection of PSA in buffer based on the PGM. The concentration of PSA was 
varied from 0 to 200 ng mL-1. Error bars: SD, n = 6. 
 
We also compared our PGM-based method with a commercialized ELISA kit (Table 5.6) on 
the performance on PSA detection in aspect to the detection limit, detection range, assay time, 
assay cost as well as portability. It looks that our PGM-based method can provide a simple, 
rapid, low cost platform with acceptable detection limit and detection range for PSA 
detection. 
 
Table 5.6 PGM-based method vs. ELISA on PSA detection 
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The only disadvantage for this platform is that two steps are required to perform the 
measurements at this research stage which is not a proper POCT.  However, this can be 
improved by future engineering design, which can separate the immunoreactions with 
enzymatic reaction automatically on strips. Therefore, the protype we designed here provides 
a potential novel concept for future POCT development and needs further optimizations for 
complete POCT and commercialization. 
  
5.4. Conclusions 
In conclusion, we have developed a simple approach for quantitative detection of 8-OHdG 
and PSA by using a low cost strip and an easily accessible PGM. The device was able to 
detect 8-OHdG concentrations in PBS as low as 0.23 ng mL-1 with a dynamic range of 0.1-
100 ng mL-1 in less than 1 h. As low as 1.26 ng mL-1 PSA in buffer can also be detected 
through the same platform just replacing the antibodies. The strip was easy to fabricate and 
convenient to operate, and the assay did not require any specialized skills or sophisticated 
instrument. In addition, because of the advantages of the PGM, the demonstration of this 
approach will provide new opportunities for the detection of other targets. 
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Chapter 6. Conclusions and future work 
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6.1. Conclusions 
This dissertation demonstrates noninvasive, rapid, visual, quantitative and convenient paper-
based POCT biosensors for disease biomarker measurements. We have developed LFS 
sensing platforms with both sandwich and competitive formats for the detections of three 
BCa related biomarkers (Crestline, MMP-9 and VEGF) and a DNA oxidative damage 
biomarker (8-OHdG), respectively. The performance of the sensor was evaluated on the 
study of nanotoxicity of three metallic particles (CuO, TiO2, CdO) on rat epithelial cells 
(CCL-149). We also successfully incorporated a paper electrode to the traditional LFS 
platform for quantitative analysis of 8-OHdG by both electrochemical and colorimetrical 
detection methods. Following this, a commercialized blood glucose meter was employed 
with an upgraded LFS platform for universal biomolecules detection, the feasibility of which 
was tested by a small molecule (8-OHdG) and a big protein molecule (PSA).  
 
Chapter 1 introduces the objectives, the background and literature review on the dissertation 
topic. Three specific aims of this dissertation are also presented. 
 
Chapter 2 summarizes the general experimental methods presented in the following chapters, 
which mainly including AuNPs based LFS fabrication, sample preparation and general 
detection mechanism. 
 
Chapter 3 addresses specific aim 1. It deals with the development of simple and rapid AuNPs 
based LFS and its applications on three BCa related biomarkers detection and an oxidative 
DNA damage biomarker detection. LFS was the simplest and earliest design of paper-based 
POCT platform and has been widely used in many diagnostic areas. In this study, AuNPs 
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based LFS was developed for colorimetrical detection of biomarkers. The reliability of the 
strip was first evaluated by the detection of three BCa related biomarkers. The developed 
LFS was able to detect the biomarkers in both standard solutions and clinical urine samples 
with high sensitivity and specificity. This kind of comprehensive test for the levels of 
multiplex biomarkers could help us to better understand the underlying physiology of BCa 
and to monitor the BCa treatment progress in addition to BCa diagnosis. In the end, by 
comparing the results obtained from the strips to those of the commercial ELISA kits, we 
concluded that the strips can provide a useful tool for quick and non-invasive BCa diagnostic. 
Following this, we also upgraded the platform by incorporating an image processing program 
"ImageJ" for semi-quantitative analysis of a small DNA oxidative damage biomarker (8-
oHdG). To the best of our knowledge, this is the first LFS-based sensing platform with the 
capability of 8-OHdG detection. The detection is quite quick (~10 minutes) and of high 
sensitivity (as low as 0.9 ng mL-1). By using the same strip, we further assessed the 
nanotoxicity of three metal oxides (CuO, TiO2, CdO) NPs on rat epithelial cells (CCL-149) 
through measuring 8-OHdG concentrations produced in cells after NPs exposure. Feasibility 
of this method was validated by the comparison with two other established methods, Alamar 
Blue assay and Electrical impedance sensing (EIS) system on the level of cell 
proliferation/viability. This sensing platform could provide a useful tool for quantitative or 
qualitative 8-OHdG measurement and a high throughput analysis capable in mass screening 
in nanotoxicological investigations in future. 
 
Chapter 4 addresses specific aim 2. It describes an upgraded sensing platform which 
combining electrochemical and colorimetric detection for the rapid measurement of 8-OHdG. 
The device takes advantage of the speed and low cost of the conventional strip test as well as 
 
105 
 
the high reliability and accuracy of the electrochemical assay. Competitive immunoreactions 
were performed on the LFS, and captured 8-OHdG on the control line was determined by 
chronoamperometric measurement with CNTs paper as the working electrode. At the same 
time, the color intensity of the test line was measured by a scanner and analyzed by ImageJ 
software. The device was able to detect 8-OHdG concentrations in PBS as low as 2.07 ng 
mL-1 by the colorimetric method and 3.11 ng mL-1 by the electrochemical method, both are 
comparable with the commercialized ELISA kit (detection limit is around 0.5 ng mL-1). Since 
the normal range of urinary 8-OHdG is 10-60 ng mL-1, either method is sensitive enough for 
8-OHdG measurement in urine samples from both healthy and non-healthy patients (The 
levels of 8-OHdG go up 2~4 times higher for the non-healthy patients depend on different 
types of diseases). In conclusion, the integrated device with dual detection methods can 
provide a rapid, visual, quantitative and feasible detection method for 8-OHdG. The 
integration of these two methods holds two major advantages over tests based on a single 
method. Firstly, it can provide double confidence on the same assay. Secondly, by involving 
two methods that differ in principle, the integration could potentially avoid false results 
coming from one method. In addition, this method do not require expensive equipment or 
trained personnel, making it suitable for use as a simple, economical, portable field kit for on-
site monitoring of 8-OHdG in a variety of clinical settings. Future efforts should be made to 
optimize the system for complete POCT development and commercialization. And the 
platform has a potential to be upgraded into a wireless-enabled biosensing system in future. 
 
Chapter 5 addresses specific aim 3. It involves the integration of a personal glucose meters 
with the traditional LFS for portable and quantitative detection of biomarkers. The PGM is 
one of the most successfully commercialized diagnostic devices on the market and has been 
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widely used by millions of diabetes patients to monitor their blood glucose levels every day. 
Nevertheless, a glucose meter is capable of detecting glucose as the unique target. Herein, we 
established a novel method that transforms the detection of the target to the detection of an 
enzyme invertase. The enzyme converts sucrose into glucose for PGM readout. The concept 
was demonstrated by using a small molecule (8-OHdG) and a large protein molecule (PSA). 
The upgraded sensing platform was able to quantitatively detect 8-OHdG and PSA by using a 
low cost strip and an easily accessible wireless-enabled PGM with high sensitivity, 
specificity, speed of performance and simplicity. In addition, because of the advantages of 
the PGM, the demonstration of this approach will provide new opportunities for the detection 
of other targets. The only defect for this platform is that two steps are required to perform the 
measurements at this research stage which is not a proper POCT.  Therefore, future efforts on 
the engineering design should be made to separate the immunoreactions with enzymatic 
reaction automatically on strips, which ensure the measurement can be done within single 
step. For future commercialization, more samples need to be tested and compared in the 
assay to ensure the reproducibility and accuracy. 
 
6.2. Future work 
The sensing platform developed in the chapter 5 for universal biomarker detection by using 
LFS and PGM could be further optimized and employed for the study of other disease 
biomarkers (both small and large molecules). The future areas of focus are: expanding the 
scope of the strip-PGM design to include other targets, further simplifying the design to 
eliminate the need for test line cutting, and optimizing the experimental conditions to acquire 
a more stable and accurate result.  
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Universality and wireless are two important factors for a sensing platform, as multiple 
detection and telemedicine are new perspectives for POCT sensor development. Therefore, a 
smartphone-enabled monitor system could be investigated and developed in future, which 
can be integrated with an upgraded LFS for instant biomarker detection, data collection and 
transmission. 
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